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Executive summary
Injectable contraceptives are associated globally with low failure rates but lower continuation rates than
such other methods as the oral contraceptive pill and intrauterine contraceptive device (IUCD). Injectable
contraceptives, notably depot medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN),
have been approved for commercial sale in India by the Drugs Controller General of India, and it is DMPA
that is the method used in India. However, injectable contraceptives have not been provided in the basket
of contraceptive methods available under the Reproductive and Child Health programme in India, largely
because of fears expressed about their appropriateness for women in India and the quality of services. As such,
injectable contraceptives are available only through private or social marketing channels, because of which their
use is limited.
Against this background, the Population Council undertook research to shed light on the feasibility and
acceptability of making injectable contraceptives more widely available to women in India. The study focused
on injectable contraceptive users, new method adopters and health care providers drawn from the facilities of
a range of reproductive health NGOs, including the Family Planning Association of India, Janani, Parivar Seva
Sanstha and Population Health Services (India). The facilities were drawn from both urban and peri-urban
areas of several states, namely, Bihar, Delhi, Jharkhand, Madhya Pradesh and Maharashtra, and were selected
purposively on the basis of the volume of injectable contraceptive users served by each clinic in the two years
preceding the study. A total of 27 facilities were selected for the study.
The study assessed these issues from three perspectives. A retrospective survey was conducted that followed
up a total of 375 women who had adopted injectable contraceptives at any time at least 12 months prior to
the interview in the participating facility, in order to assess the experiences of injectable contraceptive users,
including the decision-making process; use histories; discontinuation and switching, and factors underlying
discontinuation; side effects experienced and the acceptability of these side effects; the quality of care received,
including whether the counselling and information provided were comprehensive and follow-up appropriate,
and the overall acceptability of the method. Second, a survey of 117 women seeking contraception was
fielded that assessed, through exit interviews, women’s awareness of injectable contraceptives; contraceptive
information provided by the health care provider, including whether injectable contraceptives had been offered;
the method selected and reasons underlying acceptance or non-acceptance of injectable contraceptives. Third,
in-depth interviews were held with 16 health care providers to draw out health care provider perspectives
about the advantages and disadvantages of injectable contraceptives, the experiences of women using
injectable contraceptives, the kinds of counselling and follow-up provided to women who adopted injectable
contraceptives, and the extent to which health care providers would advocate the inclusion of injectable
contraceptives in the public health programme.
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Summary
There is a demand for injectable contraceptives
Exit interviews with women seeking to adopt contraception revealed that nine percent of women seeking
contraception at study facilities, that is, about one-fifth of those opting for a non-terminal method, had
adopted injectable contraceptives. We acknowledge that the NGO facilities in which the study was located
were well known for offering injectable contraceptives; and hence their clientele may not be representative
of all women seeking to adopt contraception more generally. Nevertheless, findings demonstrate that there is
clearly a demand for injectable contraceptives in diverse settings in India.

A number of factors inhibited women seeking contraception at study facilities from
adopting injectable contraceptives
Findings suggest a number of factors underlying the relatively limited adoption of this method. Among
women seeking contraceptive services, many of those who had not intended to adopt injectable contraceptives
were unaware of the method. Indeed, two-thirds of those who had adopted other methods reported that they
were unaware of the availability of injectable contraceptives. As most women adopted the method they had
intended to adopt prior to visiting the facility on the day of the interview, this lack of general awareness
is likely a key factor inhibiting the use of injectable contraceptives. Women who had adopted injectable
contraceptives advanced other reasons such as fear of side effects, and the cost of injectable contraceptive
repeat doses. In addition, the need to access the facility for repeat doses of injectable contraceptives was
perceived as a serious disadvantage by many; in comparison, they noted that the IUCD did not require
repeated follow-up and oral contraceptives could be easily purchased or obtained from facilities and outlets
closer to home.

Experience of side effects was widespread among injectable contraceptive users
As other studies have observed, more than four in five women who adopted injectable contraceptives had
experienced at least one side effect, largely menstrual disturbances or backache, weakness and weight gain.
However, of women who had continued using injectable contraceptives for three or more doses, a comparison
of side effects experienced following the first and third or higher order dose, suggested that side effects,
notably heavy bleeding and irregular menstrual cycles were considerably less likely to be experienced following
subsequent doses compared to following the first dose. In all, about three-fifths of all women who experienced
a side effect had complained about it to a health care provider and about half noted that the side effect
affected their ability to perform their household responsibilities, both in terms of physical inability to perform
routine tasks and in terms of the cultural proscriptions forbidding women to enter the kitchen, perform pujas
or visit a place of worship during menstruation. Indeed, women who had experienced three or more side
effects were more likely than other women to so report; women who experienced menstrual disturbances were,
on average, less likely to have complained and less likely to have reported that the side effect had affected
their ability to perform their household responsibilities than were those who had experienced other side effects.
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Method continuation was limited
Conforming with the thrust of available evidence, both global and from India, our findings suggest that
method continuation was limited. Life table continuation rates suggest that many women discontinued using
the method after the first injection, and by 12 months, just 23 percent were continuing to use injectable
contraceptives. Reasons for discontinuation centred largely around the side effects experienced, with twothirds of all those who had discontinued using injectable contraceptives, citing a health-related factor, largely
menstrual disturbances, as the reason. Many fewer cited method-related reasons (that they planned to switch
to another method, did not like the method, had doubts about it, needed a break from it or that it was
inconvenient to use), difficulties in accessing supplies, and fertility-related reasons (that they wanted to become
pregnant, were infecund or did not engage in sexual relations regularly); one woman reported use failure.
That side effects were a central reason for discontinuing injectable contraceptive use was evident from findings
suggesting that life table continuation rates were considerably lower among those who experienced both
menstrual disturbances and other side effects than among those who experienced just menstrual disturbances.
Continuation of use of injectable contraceptives, as assessed by multivariate analysis, was largely associated
with a number of socio-demographic and use-related factors. The odds that a woman had continued to use
injectable contraceptives for at least 12 months were greater among younger and better-educated women,
and those with larger numbers of children at the time of taking the first dose of injectable contraceptives,
as compared to other women, Notably, they were also greater among those who experienced fewer side
effects and were provided good quality of care. Also of interest were findings that continuation of injectable
contraceptives at early stages of use were significantly associated with whether the decision to adopt injectable
contraceptives was made jointly by the woman and her husband, suggesting that the husband’s role in
supporting women was important for method continuation at the initial stages of use.
In in-depth interviews, health care providers concurred that the leading reason for discontinuing injectable
contraceptive use was the experience of side effects, notably menstrual disturbances. Other reasons mentioned
included the inconvenience of returning to the facility every three months for re-injections and cost. Health
care providers highlighted that a range of reasons inhibited women experiencing menstrual disturbances from
continuing to use injectable contraceptives; for example, those experiencing heavy bleeding or irregular periods
feared that they had a serious disease, those experiencing amenorrhoea feared that they were pregnant, and
discontinued the method as a result; and cultural practices that forbid menstruating women from entering
the kitchen or performing religious activities, including visiting a place of worship, prompted women who
experienced heavy bleeding or irregular menstruation to discontinue using injectable contraceptives because it
affected their ability to perform these regular tasks. Several health care providers also noted that weight gain
and the long waiting time to conception following discontinuation of the method were additional reasons for
discontinuation.
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Following discontinuation, large proportions of women switched to using a different
contraceptive method
Following discontinuation of injectable contraceptive use, about three in ten women switched immediately
to another contraceptive method, a similar proportion switched to another method (including those who
switched back to injectable contraceptives) after a gap of one to three months, and about two in five women
did not adopt another method even after a three months gap. Using these two indicators of all-method
continuation, findings showed 12-month continuation rates of 45 percent and 53 percent, respectively.
In in-depth interviews, health care providers also noted that method switching was common among women
who discontinued using injectable contraceptives for method-related reasons, and that the two methods to
which women most commonly switched were tubal ligation and the IUCD.

Counselling was not comprehensive for most women who adopted injectable
contraceptives
Findings from women who had adopted injectable contraceptives suggest that although the majority had
obtained information about injectable contraception largely from health care providers, counselling was
not comprehensive in many instances. For example, while almost all women who had adopted injectable
contraceptives had been informed about the need for three-monthly re-injections and their cost, and most had
been informed about how the method works and the fact that it is a non-terminal method, fewer than three
in five had been counselled about possible side effects, what to do if problems were encountered, and the
need to return to the health care provider or facility if doubts or problems were experienced.
Exit interviews with women seeking contraception at study facilities suggest that they had similar
experiences. Few women reported that counselling had encompassed information about injectable
contraceptives and their advantages and disadvantages. Indeed, just one in four women seeking contraception
reported that they had been informed about the availability of injectable contraceptives during pre-adoption
counselling by the health care provider.
Health care provider perceptions, as espoused in in-depth interviews, differed. Health care provider
narratives suggest that counselling encompassed both the provision of information and an assessment of
the prospective client’s suitability for injectable contraceptives. Counselling was held to entail the provision
of such information as the mechanics of the method (how often it must be taken) and the kind of side
effects that may occur. All health care providers indicated that they informed women about such side effects
as amenorrhoea and heavy bleeding, and that they should return to the clinic if they experienced these.
Other side effects were mentioned less frequently (weight gain for example). Several health care providers
discussed the importance of including the husband in the counselling session, highlighting the link between
the husband’s involvement and the quality of subsequent method use, and the perception that many women
would not adopt a method without having discussed it with their husband. All health care providers
emphasised that the final decision on method use was made by the woman herself, alone or together with her
husband. Finally, while a number of health care providers noted that poor and poorly educated women found
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it more difficult than others to comprehend the information provided, and that they may not continue using
the method because of the high cost of re-injections, the large majority stressed that they would not deny
injectable contraceptives to poor and poorly educated women.

Women and providers were divided about the acceptability of injectable contraceptives
Overall, women were divided about the acceptability of injectable contraceptives. As many as one quarter of
all women could not identify a single positive feature, and a slightly larger proportion could not identify a
single negative feature of injectable contraceptives. Key positive features included that it enabled women to
control their fertility, that it was long-acting and does not require a daily routine, that it is easy to use and
that it is safe. Key negative features, as expected, were the menstrual disturbances and other health-related side
effects caused by injectable contraceptives. Women who had discontinued the method before completing 12
months of use (three doses or fewer) were more likely than those who had continued using the method for 12
months or more (at least four doses) to report negative features and correspondingly, were significantly more
likely to report such positive features as its safety and effectiveness, and its long-acting nature and ease of use
than were those who had discontinued before completing 12 months of use. Over half of women who had
used injectable contraceptives as well as the IUCD or oral contraceptive pills (prior to adoption of injectable
contraceptives or post discontinuation) reported that they preferred to use injectable contraceptives. Leading
reasons for this preference included its perceived safety, ease of use, long-acting nature and, in comparison to
oral contraceptive pills, that it does not require a daily routine.
In in-depth interviews, health care providers corroborated many of the issues raised by women who had
used injectable contraceptives and those seeking to adopt a contraceptive method. Most health care providers
noted that a number of their clients had adopted injectable contraceptives and that interest in the method
was frequently expressed. However, they were mixed about their views on the appropriateness of injectable
contraceptives as a viable method for their clientele. Almost all agreed that it is a safe and effective method,
but expressed concerns about the side effects of the method. Several health care providers indicated that
they would recommend the method to only certain categories of women, for example, those who do not
want another child, or are older. Many noted that menstrual disturbances made injectable contraceptives an
unattractive option for women, arguing that neither heavy bleeding nor amenorrhoea were acceptable side
effects for women. A number of health care providers also noted that for women intending to have another
pregnancy on discontinuation of the method; time to conception was far longer than that associated with the
IUCD or oral contraceptives. Notably, not a single health care provider acknowledged the appropriateness of
injectable contraceptives for recently delivered and lactating women.
Notwithstanding these concerns, health care providers were, for the most part, in favour of including
injectable contraceptives in the national programme in order that the basket of methods available to
women would increase and provide women with greater choice. However, they argued strongly for certain
prerequisites, such as comprehensive and sensitive counselling and effective follow-up, for example. A few
were sceptical; they believed that even with such improvements in the quality of services, few women in India
would adopt or continue using injectable contraceptives because their side effects, and notably menstrual
disturbances, would discourage most women for both health and socio-cultural reasons.
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Recommendations
The findings of the study suggest a number of priority areas for action.

Meet the demand for injectable contraceptives by including the method in the basket of
contraceptives provided in public sector facilities
Findings highlight that there is considerable interest in adopting injectable contraceptives and clearly a demand
for a safe and effective non-terminal method that allows women to control their fertility confidentially, that
does not require daily attention and that does not require to be inserted. Relatively low continuation rates
are associated with injectable contraceptives globally and the finding should not be interpreted as a lack of
demand. Indeed, the finding that more than one-fifth of all injectable contraceptive users continued the
method for 12 months reiterates that there exists a demand for the method among certain groups of women.
At the same time, evidence that many more discontinue injectable contraceptive use and immediately switch
to a different method, thereby remaining protected against unintended pregnancy, suggests that injectable
contraceptives play an important role in women’s overall contraceptive strategies. Expanding the basket of
contraceptives available to women will, therefore, enhance women’s options and enable them to select the one
whose features most suit their needs.

Include a component of injectable contraceptives in the training offered to a range of
health care providers
Findings have suggested that health care providers who serve injectable contraceptive users may not be fully
aware of the advantages and disadvantages of injectable contraceptives, the full range of side effects that
are and are not associated with injectable contraceptives, and the counselling needs of potential users. It is
important, therefore, to include a module on injectable contraceptives in the contraception-related training
offered to a range of health care providers. For example, health care providers must be made aware of the
appropriateness of injectable contraceptives for women who are recently delivered and lactating. Similarly, they
should be trained to recognise that injectable contraceptives may satisfy the needs of women at different stages
of the life cycle, for example, a newly delivered woman who wishes to space her next pregnancy, or a woman
who is not medically eligible for an IUCD or does not want to have an IUCD inserted but is looking for a
long-acting method. At the same time, they should be trained to appreciate that for some women, common
side effects would likely be an intolerable disturbance in everyday life, and hence, should be equipped to
counsel women so as to enable the woman to arrive at an informed decision about whether or not to adopt
injectable contraceptives.
Given that a number of women from our study were drawn from rural areas, it is important that training
for frontline health workers, such as ANMs, ASHAs and AWWs, should also include information about
injectable contraceptives, how they function and where they can be obtained, as well as basic information
about potential side effects and how these should be managed.
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Expand awareness of injectable contraceptives at the community level
Findings have confirmed that many women seeking to adopt contraceptives were unaware of injectable
contraceptives, and at the same time, although the method is not available through the programme, a
sizeable number of women do indeed opt for it. It is important, therefore, that efforts are made to inform
communities, and women in particular, about injectable contraceptives, how they function, their cost, and
where they can be obtained, as well as basic information about potential side effects.

Improve the quality of care and counselling provided to injectable contraceptive users
Findings suggest a disconnect between the views of health care providers on the comprehensiveness of
counselling provided and women’s views about the comprehensiveness of counselling received from health care
providers with regard to injectable contraceptives. This disconnect highlights the need for health care providers
to ensure that women are indeed making an informed choice, that they fully understand the implications of
likely side effects for their life. Health care providers have acknowledged the importance of including husbands
in the counselling session, and findings have confirmed that continuation beyond the first dose is indeed
influenced by the role of the husband in decision-making. Provided that the woman agrees, it is important
that counselling includes both the woman and her husband and that both are made fully cognisant of possible
side effects.
As far as counselling is concerned, health care providers must be trained to ensure that counselling
encompasses the full range of side effects associated with injectable contraceptives, as well as the action that
the woman should take in case these side effects are experienced; the need to ensure that the woman has
understood the implications of the method proposed, including injectable contraceptives, must be emphasised.
For example, women, and their husbands if present, must be informed that amenorrhoea, irregular menstrual
cycles and heavy bleeding occur to large numbers of injectable contraceptive users, that some women may gain
weight, and that return to fertility may be slower than in the case of other contraceptives. Counselling sessions
must also make women feel supported in case side effects are experienced, and emphasise the appropriateness
of follow-up visits and phone calls in case the woman has concerns. Our finding that continuation rates were
significantly higher among women who were provided comprehensive counselling underscores the critical role
that health care providers play in ensuring method satisfaction.

Make special efforts to inform injectable contraceptive users and potential users about
health-related side effects
Menstrual disturbances and weight gain are common and well-known side effects of injectable contraceptives,
and return to fertility is typically longer among women who discontinue using injectable contraceptives than
other methods. Women considering use of the method must be supported in making an informed decision,
given these three key concerns. Irregular prolonged bleeding, amenorrhoea and/or heavy bleeding occur among
most users of injectable contraceptives at some point while using the method, and women should be informed
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about this likelihood and the fact that side effects are typically not harmful. Although injectable contraceptives
are a reversible method of fertility regulation, women also need to be informed that since the method is longacting, it cannot easily be discontinued or removed from the body if a complication occurs or if pregnancy is
desired. Counselling sessions should be supplemented by pamphlets and easy-to-read materials that highlight
these side effects, emphasise that they are not harmful, and advise users about the action to take in case they
are experienced.

Reduce barriers to accessing supplies
Findings have shown that 16 percent of all women who had discontinued using injectable contraceptives
and between 12 percent and 28 percent of women who had discontinued using the method after various
doses reported difficulty in accessing re-supplies. The leading access-related barrier was the inconvenience
of accessing the facility every three months for re-injections. Long distances, limited freedom of movement
and unavailability of an escort, and time spent in travelling to the facility for re-injections were significant
deterrent to method continuation. Efforts are needed that enable women to obtain re-injections closer to their
homes and at reduced cost; the introduction of the method into the programme would go a long way in
doing so.

Conclusion
In short, findings suggest that there is a demand for injectable contraceptives among women, and that both
women and health care providers perceive a number of advantages associated with the method. As is well
known, injectable contraceptives may not suit the lifestyle of many Indian women and our findings have
confirmed that the method was adopted and was continued for one year or more, by relatively few women.
Nevertheless, the fact that it was adopted by one in ten women seeking contraception, and was continued for
one year or more by one in five women who adopted the method, reiterates that for a significant minority
of women, its advantages exceed its disadvantages on balance. We conclude that there is indeed a demand for
the method among this minority of women, and that the inclusion of injectable contraceptives in the basket
of methods offered under the national programme, along with appropriate emphasis on health care provider
training and on ensuring informed choice, will expand women’s contraceptive choices and help in ensuring
their reproductive rights.
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Introduction
Rationale

Janani, Parivar Seva Sanstha (PSS), and Population
Health Services (India) (PHSI)], evidence of users’

Injectable contraceptives are associated globally

experiences is sparse. Indeed, a search revealed that

with low failure rates but lower 12-month

very few studies have focused on the experiences

continuation rates than such other methods

of women using injectable contraceptives (see for

as the oral contraceptive pill and intrauterine

example, Caleb-Varkey et al., 1998; Indian Council

contraceptive device (IUCD) (Vaughan et al.,

of Medical Research, 1985; 1990; 2008; United

2008; World Health Organization, 2010; Ali and

Nations Population Fund, India, 2004; Sama, 2003);

Cleland, 2010). Injectable contraceptives, notably

while all of these explored menstrual disturbances,

depot medroxyprogesterone acetate (DMPA)

such issues as method continuation, method

and norethisterone enanthate (NET-EN), have

switching and acceptability, quality of services and

been approved for commercial sale in India by

provider perspectives on injectable contraceptives

the Drugs Controller General of India (Family

were infrequently assessed. This lack of evidence

Health International, 2010; Parivar Seva Sanstha,

makes it difficult to evaluate the effectiveness,

2004; Indian Council of Medical Research, 2008).

safety and acceptability of the method; inform the

However, injectable contraceptives have not been

debate about the feasibility of including injectable

provided in the basket of contraceptive methods

contraceptives in the programme, and provide

available under the Reproductive and Child Health

appropriate counselling for women to enable them to

programme in India, largely because of fears

evaluate various contraceptive options and make an

expressed about their appropriateness for women

informed choice about which contraceptive method

in India and the quality of services (Parivar Seva

to adopt.

Sanstha, 2004; Sarojini and Murthy, 2005). As
such, injectable contraceptives are available only

Study Objectives

through private or social marketing channels. As a
result, the use of injectable contraceptives is limited.

The objective of this report is to shed light on the

Indeed, just 0.1 percent of married women in India

feasibility and acceptability of making injectable

were using injectable contraceptives in 2005–06

contraceptives more widely available to women in

(International Institute for Population Sciences and

India. It does so from three perspectives. First and

Macro International, 2007).

foremost, it assesses the experiences of injectable
contraceptive users, including use histories,

Although injectable contraceptives have

discontinuation and switching and factors underlying

increasingly been offered by private and NGO

discontinuation; side effects experienced and the

facilities, including through the facilities of a number

acceptability of these side effects; the quality of

of health-serving NGO programmes [for example,

care received, including whether the counselling

the Family Planning Association of India (FPAI),

and information provided were comprehensive and
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follow-up appropriate, and the overall acceptability

the United Nations report on levels and trends

of the method. Second, it assesses the extent to

of contraceptive use suggests that 34 percent of

which new method adopters opt for the injectable

oral contraceptive users compared to 46 percent

contraceptive method and their motivations for

of injectable contraceptive users had discontinued

preferring injectable contraceptives or other methods.

the method during the first 12 months of use

Third, it sheds light on the perspectives of providers

(United Nations, 2006). Likewise, a recent study

of reproductive health services located in facilities

of data from 23 countries found wide variation

providing injectable contraceptives, specifically with

across countries, but noted that on average, 36

regard to the extent to which they recommend the

percent of women using injectable contraceptives

method to their clients, the kind of counselling and

had discontinued using the method within 12

information they provide, their perceptions about the

months, compared to 28–29 percent of users of oral

experiences of their clients, and the extent to which

contraceptive pills and condoms and nine percent of

they would advocate the inclusion of injectable

IUCD users (Ali and Cleland, 2010).

contraceptives in the public health programme.

As mentioned earlier, few studies from India

Background

have explored the perspectives and experiences of

Depot medroxyprogesterone acetate (DMPA) and

Available studies have addressed issues relating

norethisterone enanthate (NET-EN) are progestin-

to injectable contraceptive use through both

only formulations that are injected intramuscularly,

qualitative and quantitative designs. The single most

and work primarily by preventing ovulation and

consistent finding of these studies is the extent to

thickening cervical mucus (Ministry of Health and

which injectable contraceptives are associated with

Family Welfare and United Nations Population

menstrual disturbances. A synthesis of findings

Fund, India, 2005). They are associated with a

from these studies suggests that three-quarters or

failure rate of less than 0.3 percent with perfect

more women reported menstrual disturbances. For

use (correctly and consistently), and three percent

example, a multi-centric study of DMPA users in

with typical use (Trussell, 2007; World Health

Ahmedabad, Vadodara and Hyderabad observed that

Organization, 2010). Although used by a tiny

19 percent experienced excessive bleeding, 21 percent

minority of contraceptive users in India, injectable

experienced irregular bleeding or spotting, seven

contraceptives are globally the fourth most popular

percent reported scanty bleeding and 13 percent

contraceptive method; indeed, it is estimated that

reported amenorrhoea (United Nations Population

more than 32 million women use the method

Fund, 2004). A second multi-centric study, covering

globally (Lande and Richey, 2006) and that it

1209 women who were using NET-EN, reported

is found to be safe and acceptable to women in

that just 19 percent of those observed for the first

many developing country settings. DMPA is the

six months of use reported no menstrual disturbance;

method used in India; it is supplied largely by non-

in contrast, eight percent, 52 percent and 20 percent

governmental organisations and the private sector.

reported frequent bleeding, infrequent bleeding and

women who have used injectable contraceptives.

amenorrhoea, respectively (Indian Council of Medical

Globally, evidence suggests that injectable

Research, 2008). In another study, conducted in

contraceptives are associated with higher rates of

Gujarat, 87 percent of DMPA users reported side

discontinuation than other methods: for example,
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effects, most of which were menstrual disturbances

studies in India that have addressed this issue

(Population Council, 2003). Side effects were also

vary considerably. Two Indian studies report

found to be widespread in a study conducted in

discontinuation rates similar to those observed in the

Uttar Pradesh among 662 DMPA users: at six

international literature. For example, in 2005–06,

months, 68 percent reported side effects, mainly

the 12-month discontinuation rate among injectable

amenorrhoea (36%), scanty periods and spotting

contraceptive users was 53 percent in India (we note

(22%) and excessive menstrual discharge (7%)

that the overall percentage of women who had used

(Caleb-Varkey et al., 1998). This finding was also

injectable contraceptives was just 0.1%), compared

observed in a study of 80 women who had adopted

to 20 percent among women using the IUCD and

injectable contraceptives from a facility in Karnataka:

49 percent among those using oral contraceptive

65 percent experienced amenorrhoea and 70 percent

pills (International Institute for Population Sciences

experienced spotting (Rai, Prabakar and Nair, 2007).

and Macro International, 2007). The two multi-

A study that compared monthly and bimonthly

centric studies that followed women up to 12

injections of two preparations of Norethisterone

and 24 months, observed that 35–44 percent had

Enanthate among two groups of women found

discontinued use of NET-EN by 12 months (Indian

that the side effects reported at 12 months were

Council of Medical Research, 1990; 2008). In

bleeding-related (12–15%) and amenorrhoea (4–7%)

contrast, other studies noted considerably higher

(Indian Council of Medical Research, 1990).

discontinuation rates. For example, the study of

Likewise, a qualitative follow-up of 50 DMPA users

injectable contraceptive users in various settings of

in Delhi found that 25, 16 and 12 women had

Uttar Pradesh found discontinuation rates as high

experienced amenorrhoea, excessive bleeding and

as 56 percent and 71 percent after the first and

irregular bleeding, respectively (Sama, 2003). Studies

second dose of DMPA, that is, by three and six

have noted that menstrual disturbances, notably

months, respectively (Caleb-Varkey et al., 1998), the

amenorrhoea, increased over time: while 61 percent

assessment of DMPA clients of two NGOs observed

of DMPA users experienced menstrual disturbances

that as many as 70–80 percent had discontinued use

overall, percentages ranged from 77 percent after the

at 12 months (Parivar Seva Sanstha, 2004), and the

first dose to 90 percent among those who continued

facility-based study of DMPA clients in Karnataka

to use the method for 10 or more doses (Parivar

reported a discontinuation rate of 43 percent at six

Seva Sanstha, 2004). Other side effects reported by

months (Rai, Prabakar and Nair, 2007).

women in these studies included weight gain, pain,

Notwithstanding widespread side effects and high

vaginal discharge, hot flushes and weakness (Sama,

rates of discontinuation, the injectable contraceptive

2003; Caleb-Varkey et al., 1998; United Nations

method was acceptable to many (70–79%), as

Population Fund, India, 2004; Parivar Seva Sanstha,

reported in two studies that explored acceptability

2004).

(United Nations Population Fund, India, 2004;

Internationally, discontinuation rates associated

Indian Council of Medical Research, 2008).

with injectable contraceptives range from 44

Two studies have addressed the quality of

percent (World Health Organization, 2010) to

care received by injectable contraceptive users.

56 percent (Vaughan et al., 2008) at 12 months.

Their findings suggest that women were not

Discontinuation rates observed among the few

appropriately screened (Sama, 2003) and were not
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given information about the possible side effects

Table 1.1, highlight the well-known differences

and what to do in case of side effects (Population

in socio-demographic indicators between such less

Council, 2003; Sama, 2003). For example, in urban

developed states as Bihar, Jharkhand and Madhya

Gujarat, just 28 percent of 184 DMPA clients were

Pradesh on the one hand, and better developed

informed about the possible side effects of injectable

ones such as Delhi and Maharashtra on the other.

contraceptives and 22 percent about what to do in

For example, female literacy rates ranged from

case of side effects (Population Council, 2003).

53–60 percent in the less developed states to
76–81 percent in the better developed ones; the

In summary, in India, very few studies have

total fertility rate ranged from 3.1–4.0 in Bihar,

focused on injectable contraceptive use. Almost all

Jharkhand and Madhya Pradesh to 2.1 in Delhi and

of these were conducted in the 1990s and early

Maharashtra; the infant mortality rate ranged from

2000s and suggest varying but low levels of method

28–30 in Delhi and Maharashtra to 42–62 in Bihar,

continuation, widespread experience of menstrual

Jharkhand and Madhya Pradesh; and the percentage

disturbances, and poor counselling and quality of

of women reporting skilled attendance at delivery

services. Notwithstanding these findings, women

ranged from 28–33 percent to 64–69 percent in

in a couple of studies reported that injectable

these states, respectively.

contraceptives were a convenient and acceptable
method in principle.

The pattern was somewhat different with regard
to other indicators. The child sex ratio varied

Study Setting

widely between study states. It was far below the
national average in Delhi and Maharashtra, well

Given the low prevalence of injectable contraceptive

above it in Bihar and Jharkhand, and similar to the

use in India, a community-based study was not

national average in Madhya Pradesh. Contraceptive

feasible. The study therefore followed up injectable

use patterns also varied. Overall contraceptive

contraceptive users drawn from the facilities of a

prevalence ranged from 34–36 percent in Bihar

range of reproductive health NGOs, including the

and Jharkhand to 56 percent in Madhya Pradesh

Family Planning Association of India, Janani, Parivar

and 67 percent in both Delhi and Maharashtra. A

Seva Sanstha and Population Health Services (India).

similar pattern emerged with regard to the unmet

The facilities were drawn from both urban and peri-

need for contraception, which ranged from 23

urban areas of several states, namely, Bihar, Delhi,

percent in Bihar and Jharkhand to 8–11 percent in

Jharkhand, Madhya Pradesh and Maharashtra, and

Delhi, Madhya Pradesh and Maharashtra. Use of

were selected purposively on the basis of the volume

modern non-terminal methods was, for the most

of injectable contraceptive users served by each clinic

part, limited: it ranged from 5–7 percent in Bihar,

in the two years preceding the study. As mentioned

Jharkhand and Madhya Pradesh, to 12 percent in

earlier, the injectable contraceptive DMPA, approved

Maharashtra and 33 percent in Delhi. Awareness of

by the Drugs Controller of India, is the method

injectable contraceptives among both women and

used in India and, as such, was the injectable

men was considerably more widespread in Delhi

contraceptive offered to women in our study.

than in any other state: 81 percent versus 33–66

The socio-demographic and reproductive health

percent among women, and 69 percent versus 38–48

indicators of the study states, presented in

percent among men.
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5
2.7
47

20103
48

4.0

29.3

19.9

47.9

66.1

22.8

4.5

34.1

53.3

73.4

933

916

103.8

Bihar

30

2.1

64.1

58.9

68.7

81.2

7.8

32.7

66.9

80.9

91.0

866

866

16.8

Delhi

42

3.3

27.8

18.3

44.7

41.5

23.1

7.3

35.7

56.2

78.5

943

947

33.0

Jharkhand

62

3.1

32.7

26.2

38.2

54.4

11.3

7.2

55.9

60.0

80.5

912

930

72.6

Madhya
Pradesh

28

2.1

68.7

64.6

39.5

32.6

9.4

11.7

66.9

75.5

89.8

883

925

112.4

Maharashtra

Note: aAges 7 and above
Sources: 1Office of the Registrar General and Census Commissioner, India, 2011a, 2International Institute for Population Sciences and Macro International, 2007, and
3Office of the Registrar General and Census Commissioner, India, 2011b.

Infant mortality rate,

Total fertility rate,

46.6

38.7

2005–062

Skilled attendance at delivery (%), 2005–062

Institutional delivery (%),

47.9
2005–062

   Men

12.8
52.6

2005–062:

   Women

Awareness of injectable contraceptives (%),

Unmet need for contraception (%),

2005–062

Current contraceptive use (any method) (%),
10.1

65.5

82.1
56.3

(%),

20111

914

940

Modern non-terminal contraceptive use (%), 2005–062

literacya

(%),

20111

20111

2005–062

Female

Male

literacya

Child sex ratio (Females per 1,000 males),

Sex ratio (Females per 1,000 males),

1,210.2

Total population (millions), 20111
20111

India

Socio-demographic characteristics

Selected socio-demographic characteristics of study states

Table 1.1
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Study Design

that assessed, through exit interviews, women’s
awareness of injectable contraceptives, the method

As described above, the study was conducted in

selected and reasons underlying acceptance or non-

selected facilities of various reproductive health

acceptance of injectable contraceptives.

NGOs in India. From these NGOs, a total of 27

In-depth interviews with health care providers:

facilities were selected purposively on the basis of
their records of first-time injectable contraceptive

In-depth interviews with health care providers

clients served during the calendar year 2010. More

were conducted to draw out provider perspectives

specifically, we perused the monthly reports of all

about the advantages and disadvantages of

NGOs and selected those facilities that reported

injectable contraceptives, the experiences of women

an average of 25 or more first-time injectable

using injectable contraceptives, and the kinds of

contraceptive clients over the period March

counselling and follow-up provided to women who

to September 2010. The study included three

adopted injectable contraceptives.

components, namely, a survey of first-time injectable

Study samples and coverage

contraceptive users, exit interviews with women
seeking contraception, and in-depth interviews with

Samples for all three components of the study were

contraceptive service providers from participating

drawn from among the clients and providers of the

facilities.

27 selected facilities. Details are provided in
Table 1.2.

Survey of injectable contraceptive users: A
retrospective study design was employed in which

Survey of injectable contraceptive users: Our study

women who had initiated injectable contraceptive use

design called for a sample size of 360 women who

any time during March to September 2010, at least

had initiated injectable contraceptive use during the

12 months prior to the interview in the participating

recruitment period, roughly 12–21 months prior

facility, were followed up, to assess their experiences

to the interview. This number includes inflation to

with the method. While a prospective design

take into account a cluster effect, which we assumed

has many advantages, for example that it enables

to be 20 percent. Further, given that the address

researchers to obtain experiences on the day of

or telephone number provided by many clients to

method adoption and at regular intervals thereafter,

the clinic may have been incomplete, inaccurate or

and consent procedures are simpler, it is more time-

obsolete (as we were following up on clients who

consuming and costly. Hence, a retrospective design

had visited the clinic at least 12 months prior to the

was used. In order to assess use patterns, a calendar

survey), we recognised that follow-up of all listed

was employed that recorded women’s monthly family

women was unlikely and unrealistic. Indeed, going

planning use and pregnancy status/outcomes between

by the experience of previous follow-up studies

January 2009 (prior to the adoption of injectable

and by personal communications with the NGOs

contraceptives) and the month of interview, thereby

providing services, we assumed that as a result of

covering the periods prior to and following the

loss to follow-up, and, to a much lesser extent,

initiation of injectable contraceptive use.

refusal to participate in the study, we would be able
to interview no more than one half to two-thirds of

Exit interviews with women seeking contraception: A

clients who had adopted the injectable contraceptive

survey of women seeking contraception was fielded
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Table 1.2

Coverage of the study

Number of injectable contraceptive
users followed-up and interviewed

Number of
women seeking
contraceptive
services who
participated in
exit interviews

Number of indepth interviews
with health care
providers

State

Number of
clinics included
in the sample

Bihar

12

94

50.5

45

4

Delhi

1

99

43.0

34

1

Jharkhand

7

108

60.7

14

5

Madhya Pradesh

3

23

52.3

4

2

Maharashtra

4

51

50.0

20

4

27

375

50.7

117

16

Total

Interviewed

Response rate

method 12 or more months prior to the interview.

interviewed women who sought contraceptives from

Hence, we aimed to make efforts to reach at least

the 27 facilities from which our sample of women

600 clients in order to ensure a total of at least 360

who had adopted injectable contraceptives was

interviewed women.

drawn. For this component of the study, interviewers
spent two to three days in each facility and

The 27 selected facilities yielded a total of 740

interviewed all the women who sought contraception

women who had adopted injectable contraceptives

from that facility, irrespective of the method

between 12 and 21 months prior to the survey and

adopted. The exit interviews sought to understand

whose addresses appeared to be complete. Efforts

the extent to which the health care provider had

were made to reach all of these 740 women, and

offered the woman the injectable contraceptive

all those contacted were invited to participate in

method, factors underlying the adoption of the

the study. Respondents thus included both those

method finally selected, and, more specifically, why

who were still using the method at the time of

the injectable contraceptive method was or was

interview, as well as those who had discontinued the

not adopted. A total of 117 women who sought

method and were either not using any method, had

contraceptive services from the study facilities and

switched to another method, or had taken a break

who agreed to be interviewed participated in the exit

and returned to using injectable contraceptives by

interviews.

the time of the survey. A total of 375 women were
successfully interviewed, giving a response rate of

In-depth interviews with health care providers:

51 percent. The majority of women (82%) were

In-depth interviews were held with at least one

interviewed in their home; a few, 10 percent and

health care provider from each study facility who

eight percent, were interviewed telephonically and at

had provided injectable contraceptive services to at

the facility, respectively.

least 25 women in the 12 months preceding the
study. A total of 16 in-depth interviews were thus

Exit interviews with women seeking contraception:

conducted, each lasting one to two hours.

In a secondary component of the study, we
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Data collection

the past; information provided by the health care
provider on various methods of contraception;

Data collection for all three components of the

factors underlying the final choice of method,

study was conducted simultaneously and took place

and specifically for choosing or not choosing the

between June and November, 2011. Two structured

injectable contraceptive method, and the quality of

instruments were used to collect data from injectable

care that they had received.

contraceptive users, and women seeking contraceptive

Guidelines for in-depth interviews addressed

services from study facilities. In-depth interview
guidelines were used to interview health care

such issues as provider perspectives about injectable

providers. Almost all interviews were held face-to-

contraceptives; their suitability for different groups

face; some 36 injectable contraceptive users opted for

of women; the experiences of clients who had

a telephonic interview.

used injectable contraceptives, notably with regard
to duration of use, side effects and menstrual

The questionnaire for injectable contraceptive

disturbances experienced; severity of and action

users was designed to gather background information

taken for side effects, and the experiences of clients

of the women as well as their contraceptive histories

who had adopted injectable contraceptives versus

over the 36 months preceding the interview, a period

other contraceptive methods. We also probed aspects

that also covered the 12–21 month period following

of quality of care, including, for example, the

the adoption of injectable contraceptives. As such,

kind of information that they provided to women

a calendar was employed, that obtained information

seeking contraceptives, and recommendations on the

month-wise about method use, discontinuation,

advisability of including injectable contraceptives in

method switching, and, if pregnancy occurred, its

the basket of methods provided in the public health

date and outcome. Aside from this, the interview

system.

probed women’s decision-making process, side effects

A team of five female interviewers and three male

experienced and the acceptability of these side
effects, reasons for discontinuation, the perceived

coordinators conducted the interviews. While the male

acceptability of injectable contraceptives, the quality

coordinators did not conduct interviews with women,

of care received, including whether counselling

they tracked respondents, facilitated contact between

and information provided were comprehensive and

respondents and interviewers, and conducted in-depth

follow-up appropriate, factors that posed obstacles

interviews with health care providers. Investigators

to the continuation of the injectable contraceptive

underwent a three-day training programme that

method, and, for those who had experience with

comprised a combination of classroom sessions and

other contraceptive methods, their assessment of

mock interviews. Training focussed on interviewing

the relative advantages and disadvantages of the

methods, the details of the questionnaire, and research

injectable contraceptive method.

ethics, with particular reference to this study, and the
need to maintain confidentiality.

The exit interview questionnaire also obtained

The study instruments were prepared in English,

background information of women seeking
contraceptive services, but focused on a few issues,

translated into Hindi, and pre-tested. In-depth

namely, the method adopted on the day of interview

interviews were taped, transcribed and translated into

and other methods that may have been used in

English.

8

Chapter 1: Introduction

Analysis

regression analysis was conducted to ascertain
the relationship between injectable contraceptive

Data from the survey of injectable contraceptive

continuation and a range of socio-demographic and

users and of women seeking contraceptive services

use-related factors.

were entered in CSPro 4.0 and analysed using

For textual data, a coding scheme was developed

PASW statistics 18. Analysis is largely descriptive.
Life table techniques were used to derive injectable

and transcripts were coded in ATLAS.ti 6.0 using

contraceptive continuation and discontinuation

this coding scheme. The coded blocks of text

rates. As such, segments of use were employed

related to specific themes, for example, negative

as units of analysis in the construction of the

and positive features of injectable contraceptives,

life table for discontinuation. A segment is an

side effects experienced by clients, content of

uninterrupted period of use of the method. The

counselling provided to users and potential users,

life table technique allows for the inclusion of both

and recommendations for the inclusion of injectable

complete and incomplete segments (for example,

contraceptives in the national programme. These

those continuing to use the method at the time of

blocks were analysed to capture typical patterns.

interview) of use in an analysis and are considered

Ethical issues and consent procedures

to be the most appropriate way of assessing the
continuity of contraceptive use (Trussell and Kost,

We recognised that in both the survey of injectable

1987). Segments of use are divided into monthly

contraceptive users and of women seeking

intervals, measured from the time of beginning

contraception in the selected facilities, serious

the segment. The construction of life tables for

ethical concerns arose. Primary among these was

discontinuation rates, for example, starts with the

the fact that women’s right to confidentiality could

calculation of month-by-month discontinuation rates.

be violated if the researchers approached women

These rates are then linked together to obtain a

directly. Hence, the research team did not make

cumulative continuation or discontinuation rate over

the initial follow-up contact with women in both

a period of time. Although our calendar collected

surveys. In the case of women who had adopted

histories from January 2009, continuation rates have

injectable contraceptives 12–21 months earlier, it

been calculated for the first segment of injectable

was a staff member of the facility from which the

contraceptive use, that is, from the month in which

woman had obtained her injectable contraceptive

injectable contraceptives were adopted (March to

supplies who made the initial contact. It was the

September, 2010) to the month of interview (June

responsibility of the facility staff member to describe

to September, 2011). Hence, for example, only the

the study—its objectives and procedures—to the

first segment of use is considered for women who

client, emphasise that neither abortion nor any other

discontinued using the method and then initiated it

services would be affected and seek initial consent

again after some time.

from the woman. In the case of the facility-based
component, the clinic administrator obtained initial

We also compared factors underlying the
continuation of injectable contraceptive use among

consent from all women seeking contraception

women who had used the method for at least nine

to permit a study interviewer to approach them.

months with those who had discontinued using

Once initial consent was provided, a research team

the method before that time. Multivariate logistic

member approached the client, sought consent once
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more, and made an appointment to interview her

such issues as method discontinuation and switching,

at a suitable time and place. Once consent was

side effects experienced, reasons for discontinuation

thus obtained, the woman was recruited into the

and method acceptability. Chapter 4 addresses the

study and interviewed. In contrast, a research team

perspectives and experiences of women seeking

member shared a detailed consent form with health

contraception at study facilities; it focuses on the

care providers and sought their written consent for

method selected and factors influencing the adoption

participating in in-depth interviews.

of injectable contraceptives or other non-terminal
methods. Chapter 5 documents the perspectives

The study was approved by the Ethics Committee

of health care providers, their perceptions of their

of the Family Planning Association of India.

clients’ experiences, the extent to which they

Structure of this report

encourage or dissuade their clients from adopting

This report has five main sections apart from this

about incorporating injectable contraceptives in

introductory chapter. Chapter 2 describes the socio-

the national programme. Chapter 6 summarises

demographic characteristics of respondents. Chapter

the findings of this study and offers programmatic

3 addresses the perspectives and experiences of

recommendations with regard to women’s experiences

women who had adopted injectable contraceptives

and perspectives on expanding access to injectable

12–21 months prior to the interview; it focuses on

contraceptives.

injectable contraceptives, and their recommendations
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Chapter 2

Social and demographic characteristics
of respondents
This chapter presents the socio-demographic profile

old. They were relatively well educated: for example,

of respondents, including both women who had

while about one-quarter (26%) had never been to

adopted injectable contraceptives 12–21 months

school, more than one-third had completed high

prior to the survey, and those seeking to adopt

school (36%). Women who had adopted injectable

contraception at study facilities during the period of

contraceptives reported an average score of 9.8 on

the survey.

the wealth index (of a maximum of 13). Work
profiles suggest, moreover, that just 16 percent were

Table 2.1 presents the socio-demographic

engaged in wage-earning activities. Almost half of all

characteristics of respondents. While most indicators

women, 48 percent, resided in nuclear families and

are simple percentages, we note that household

four percent reported that their husband lived away

economic status was measured using an index,

from them for extended periods of time. As far as

composed of household asset data on the ownership

fertility levels are concerned, injectable contraceptive

of selected durable goods and access to amenities;

users had an average of 2.6 surviving children, with

the index was adapted from the household

two-fifths reporting three or more surviving children.

standard of living index used in the Youth in India:
Situation and Needs study (International Institute for

Among the 117 women seeking to adopt

Population Sciences and Population Council, 2010).

contraception (Column 3 of Table 2.1), profiles were

The index was constructed from the following items,

largely similar. Among this group, 80 percent were

with scores assigned as follows: source of lighting

Hindu and 20 percent belonged to scheduled caste

(2 for electricity, 1 for kerosene, solar light, and 0

or tribe households. On average, respondents were

for others); source of drinking water (2 for piped

aged 28 years, more than two-fifths (44%) had never

water, hand pump, covered well, etc; 0 for others);

been to school, and just 12 percent were engaged in

toilet facility (3 for flush toilet, 2 for pit toilet or

wage-earning activities. As far as household economic

public toilet, and 0 for no facility); 2 each for the

status was concerned, the average score on the

ownership of a television, refrigerator or land/mobile

wealth index was 8.5 (of a maximum of 13). More

phone, and 0 for none. Scores were cumulated; the

than two-fifths (44%) resided in nuclear families

index therefore ranges from 0 to 13.

and five percent reported that their husband lived
away from them for extended periods of time. As far

Among the 375 women who had used injectable

as fertility levels are concerned, women seeking to

contraceptives, Column 2 of Table 2.1 shows that

adopt contraception had an average of 2.9 surviving

82 percent of all respondents were Hindu and

children, with almost three in five reporting three or

22 percent belonged to scheduled caste or tribe

more surviving children.

households. Respondents were, on average, 29 years
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Table 2.1

Socio-demographic profile of respondents
Women who had adopted
injectable contraceptives,
March-September, 2010

Socio-demographic characteristics

Women seeking to adopt
contraception,
June-September, 2011

Number of women

375

117

Age of women (years) (Mean)

28.7

27.9

Education (%)
No education
Completed Class 10 or higher

25.9
36.0

43.6
18.8

Religion (%)
Hindu
Muslim
Other

82.4
14.4
3.2

79.5
18.8
1.8

Caste (%)
Schedules castes
Scheduled tribes
Other backward castes
General

12.0
9.9
48.5
29.6

16.2
3.4
54.7
25.6

Work statusa (%)
Worked for wages in the last year

16.3

12.0

Wealth index (0 to 13) (Mean)

9.8

8.5

47.5

44.4

48.3

50.4

4.3

5.1

0.8
18.1
41.1
40.0
2.56

1.7
6.0
34.2
58.1
2.86

25.1
26.7
28.8
6.1
13.3

40.2
29.1
10.3
3.4
17.1

100.0

100.0

Family type (%)
Nuclear: Co-resides with husband/children only
Extended/Joint: Co-resides with husband and/or
other family members
Extended/Joint: Lives with other family members,
but husband lives away for extended periods of
time
Total number of surviving
0
1
2
3 or more children
Mean

childrena

(%)

State (%)
Bihar
Delhi
Jharkhand
Madhya Pradesh
Maharashtra
Total

Note: aAt the time of accepting the first dose of injectable contraceptives among women who adopted injectable contraceptives
during March-September, 2010 and were interviewed retrospectively, and on the day of the interview for women seeking
contraception.
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We note, finally, that our state-wise distribution

30 and 39 years, six each aged between 40 and 49

of respondents varied considerably as a result of our

years and 50 years and above. As far as educational

purposive sampling design. More than three-quarters

qualifications are concerned, 14 held MBBS degrees,

of both injectable contraceptive users and women

and two held BAMS (Bachelor of Ayurvedic

seeking contraceptive services came from three

Medicine and Surgery) degrees. Finally, most health

states—Bihar, Jharkhand and Delhi.

care providers had been practising for extended
periods of time. Indeed, the median number of

The socio-demographic profile of the 16 health

years during which health care providers had been

care providers interviewed in-depth shows that all

practising was 22 years, ranging from four to 37,

16 were female. They ranged in age from 30 to 78

with just four health care providers reporting that

years, with four health care providers aged between

they had been practising for less than ten years.

13

Chapter 3

Experiences of women using injectable
contraceptives
This chapter explores the experiences of women

prior to adoption of the method or in the course of

who had adopted injectable contraceptives 12–21

seeking contraceptive services. Findings, presented

months prior to the study. It covers a range of

in Table 3.1, suggest that the majority of women

issues: their sources of information about injectable

had heard about injectable contraceptives from a

contraceptives prior to adopting the method and

health care provider or facility (62%), either in the

the decision-making process leading to injectable

course of seeking contraceptive services, or in the

contraceptive use; the duration of use and reasons

course of a previous visit. As many as 46 percent of

for discontinuation; side effects experienced, their

the women had been informed about the method

severity, and action taken to address them; method

by a private sector provider. It is notable, however,

switching experiences; and acceptability of the

that although the method is not available through

method, namely, perceptions about its best and worst

the public sector, as many as one in five women

features.

reported having heard about injectable contraceptives
from a public sector provider, and specifically a nurse

As mentioned earlier, our sample comprised

or Auxiliary Nurse Midwife (ANM) (15%) and an

women who had adopted injectable contraceptives

ASHA (Accredited Social Health Activist) or AWW

during the period March to September 2010, such

(Anganwadi Worker) (5%). In addition to health

that the vast majority of women had adopted the

care providers, a large proportion (47%) of women

method 12–21 months prior to the interview,

reported that they had heard about the method

although, in a few cases, adoption had taken place

from their informal networks, most often a friend or

16–21 months prior to the interview. Almost

neighbour (30%) and/or their husband (10%).

all women who had adopted the method (95%)
reported that they were issued a card at the time

Women were asked, in addition, about which

of getting the first dose of injectable contraception;

contraceptive method or methods they had wanted

however, only one quarter (27%) of women

to adopt when they visited the facility to obtain

were able to locate the card and present it to the

contraceptive services. As Table 3.2 suggests, two-

interviewer.

thirds of all injectable contraceptive users had
planned to adopt injectable contraceptives when they

Decision-making process

arrived at the facility for contraceptive services 12–21
months earlier, clearly suggesting that many women

Women who had adopted injectable contraceptives

had come to the facility with some prior awareness

were probed about the source from which they had

of the method. Nevertheless, about 16 percent

first heard about injectable contraceptives—whether

of all injectable contraceptive users had originally
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Table 3.1

Source of information among women who had adopted injectable contraceptives: Percentage
of women who had heard about injectable contraceptives prior to or in the course of seeking
contraceptive services by source of information
Women who had adopted
injectable contraceptives

Source of information
Health care provider/facility

62.4

Private doctor/Clinic

45.6

Public sources

20.3

Primary Health Centre

0.8

Community Health Centre

0.3

Nurse/ANM

14.7

ASHA/AWW

5.3

Family, friends and neighbours

46.7

Family members

19.5

Husband

10.1

In-laws/Parents

2.4

Other relatives (aunt/sister-in-law/sister/other)

7.5

Friend(s) and neighbour(s)

29.9

Other
Public campaigns (poster/radio/vehicle announcement)

1.1

Number of women

375

Note: Multiple responses possible.

intended to adopt a different method: nine percent

to adopt was not appropriate for them (50%; not

had intended to be sterilised and seven percent to

shown in table). In a few cases, the woman and/

adopt a different non-terminal method—six percent

or her husband had changed their mind after being

to have an IUCD inserted, and about two percent

counselled: 12 percent reported that they were afraid

to use oral contraceptives or the condom. Almost

of the side effects of the method they had originally

one-fifth (19%) were undecided about which method

selected, and eight percent reported that their

to adopt when they visited the facility. Among the

husband did not permit her to adopt the method

16 percent who had visited the facility intending

they had intended to use (not shown in table).

to adopt a specific method other than injectable

Table 3.3 presents the role of the woman herself

contraceptives, the health care provider had played

and others in the final decision to adopt injectable

a key role in influencing the adoption of injectable

contraception. It is notable that the large majority

contraceptives: one half of these women reported

of women (86%) reported that they had made the

that the health care provider had counselled them

final decision to adopt injectable contraceptives on

and suggested that the method they had intended

their own, with or without the involvement of other

15
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Table 3.2

Intended contraceptive method: Percentage of women by contraceptive method they had intended
to adopt prior to visiting the facility
Women who had adopted
injectable contraceptives

Intended contraceptive method
Injectable contraceptives*

66.7

Other non-terminal methods

6.9

Intrauterine contraceptive device

5.6

Oral contraceptive pill

1.3

Condom

0.3

Terminal method
Female sterilisation

8.8

Undecided: no method in mind

19.2

Number of women

375

Note: Multiple responses possible; *64.8 percent reported that they had intended to adopt injectable contraceptives and no
other method.

decision-makers. Others participating in the final

over one half (52%) of all women reported that they

decision included the husband (63%) and a health

had made the decision jointly with their husband;

care provider (12%); the mother-in-law and others

about 11 percent of the women reported that their

were rarely involved. It is notable that just a little

husband had made the final decision without them.

Table 3.3

Contraceptive decision-making role: Percentage of women by lead decision-maker(s) in the final
selection of injectable contraceptives
Women who had adopted
injectable contraceptives

Decision-maker
Health care provider

12.0

Doctor

11.2

Nurse

1.2

Self

85.6

Other
Husband*

62.7

Mother-in-law

1.3

Friend, other

0.8

Nunber of women

375

Note: Multiple responses possible; *52 percent made the decision together with wife.
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Injectable contraceptive counselling

Also of concern was the finding that of those
informed about side effects, relatively small

Women were asked about the kind of counselling

proportions were informed about the range of

they had received when they opted for injectable

side effects experienced, in general, by women

contraceptives. Findings, presented in Table 3.4,

using injectable contraceptives. Hence, as seen in

suggest that counselling was not comprehensive for

Table 3.5, of the 148 women counselled about

most women. Almost all reported that they had

side effects, fewer than two-thirds (63%) were told

been informed about the three-monthly cycle of

about the possibility of experiencing amenorrhoea,

injectable contraceptives and its cost (98% and 91%

less than half about the possibility of experiencing

respectively), 77 percent had been informed about

heavy bleeding (47%), and 35 percent about the

how the method works, and two-thirds had received

possibility of experiencing irregular periods. Few

an information brochure on the method from the

women reported being told about other side effects:

health care provider. However, fewer than one

spotting (12%), weight gain (16%), backache (4%)

half had been counselled about other matters: for

and weakness (5%). Given the large proportion

example, just 56 percent had been informed about

of women who experienced side effects, it is of

the possible side effects of the method, 34 percent

concern that so few were informed about the links

about what they should do if they encountered any

between injectable contraceptive use and menstrual

problems or side effects, and 42 percent had been

disturbances, in particular.

informed that they should return to the service
provider or facility if they had any doubts or
experienced any problem.

Table 3.4

Injectable contraceptive counselling and information obtained from health care providers
Counselling and information

All women

Access to written materials
Received a brochure on injectable contraceptives from the health care provider

68.0

Had seen a poster on injectable contraceptives at the facility

44.8

Information provided about
How injectable contraceptives work

77.3

The non-terminal nature of injectable contraceptives and need for three–monthly follow-up
visits for repeat injections

98.1

Cost of each injection

90.9

Possible side effects of injectable contraceptives

55.5

Action to be taken if problems or side effects are encountered

33.6

Told to come back to the clinic or contact health worker if she has doubts/side effects

41.9

Number of women

375
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Table 3.5

Information provided by health care providers about side effects: Percentage of women who were
informed about possible side effects of injectable contraceptives by type of side effect discussed
Side effects

Women who were informed about side effects

Heavy bleeding

46.6

Spotting between menstrual periods

12.2

Irregular periods

35.1

Amenorrhoea

62.8

Backache

4.1

Weakness

4.7

Weight gain

16.2

Number of women

148

Side effects experienced

Almost three in five women (58%) reported
experiences of other side effects related to the use

Women were asked about the side effects experienced

of injectable contraceptives, including weakness

after taking each dose of the injectable contraceptive:

(40%), backache (27%), weight gain (16%) and

a general question was first posed, asking women to

anxiety or stress (15%). A large proportion of

spontaneously identify the side effects experienced,

women reporting such other side effects also did so

and this was followed by probing questions that

spontaneously (38%, not shown in table). We note

inquired about the experience of any other side

that the majority of women who reported other

effects that may have been experienced. Table 3.6

side effects also reported one or more menstrual

(Column 2) presents women’s experiences as reported

disturbances. Indeed, just 22 women (about 10%

both in direct questioning and after probing.

of women reporting other side effects) did not also

Findings suggest that large proportions of users

report menstrual disturbances. Of these 22 women,

reported the experience of one or more side effects.

13 reported weakness, six reported weight gain, four

In all, 82 percent reported one or more side effects

reported backache, three reported weight loss, two

that occurred following the first or subsequent doses

reported anxiety or stress and three reported swelling,

of injectable contraceptives; three-quarters of these

pain and so on (not shown in table).

women (74%) reported a side effect spontaneously

Columns 3 and 4 of Table 3.6 show the extent

(not shown in table). About three-quarters of
all women (76%) had experienced one or more

of side effects experienced by women who had

menstrual disturbances: indeed, between one-fifth

discontinued after the first or second dose, and

and two-fifths had experienced such disturbances

those who had continued for three or more doses

as amenorrhoea, heavy bleeding and irregular

of injectable contraceptives, respectively. Overall,

periods. Further, almost all of these women reported

similar proportions of women in both groups

menstrual disturbances spontaneously (68%; not

reported one or more side effects. Findings further

shown in table).

show that while similar proportions of women
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in both groups had experienced one or more

modestly between the first and second doses, and

menstrual disturbances, women who continued

also levelled off thereafter.

using injectable contraceptives beyond the second

In order to better understand the action taken

dose were significantly less likely than shorter-term

by women who experienced various side effects,

users to report such menstrual disturbances as heavy

women who had experienced a particular side effect

bleeding and irregular periods, and significantly

were asked whether they had complained about

more likely to have experienced amenorrhoea. Other

it to a health care provider. Findings reported in

side effects were slightly more likely to have been

Table 3.7 suggest that overall, some 62 percent of

experienced by women who had discontinued using

all women, and 59–60 percent of those experiencing

the method after the first or second dose compared

any menstrual disturbance or any other side effect,

to longer-term users; indeed, longer-term users were

had brought their side effect to the attention of a

significantly less likely to report weakness, weight

health care provider. Among women experiencing

loss and anxiety or stress than shorter-term users, but

different types of side effects, those who had

were significantly more likely to report weight gain.

experienced menstrual disturbances together with

In order to assess the extent to which the

other side effects, and those reporting three or more

experience of side effects diminished with subsequent

side effects were most likely to have complained to a

doses of injectable contraceptives, we explored

health care provider (80% and 84%, respectively). In

experiences after each dose among women who had

contrast, fewer women experiencing only menstrual

continued to use the method for three or more

disturbances (32%), only other side effects (27%) or

doses. Findings show a mixed picture (Columns 5,

fewer (one or two) side effects (44%) reported that

6 and 7 of Table 3.6). The experience of menstrual

they had complained about their side effect(s) to a

disturbances fell consistently but mildly with

health care provider.

continued use of injectable contraceptives—from

A roughly similar picture emerged when women

47 percent after the first dose to 35 percent after

were also asked whether the side effect(s) had

the third dose, with proportions experiencing such

affected their performance of regular household

side effects as heavy bleeding declining significantly

responsibilities, both in terms of physical inability

between the first and second doses, while the

to perform routine tasks and in term of the cultural

experience of amenorrhoea declined modestly.

proscriptions forbidding women to enter the kitchen,

Experiences of other side effects suggest that overall,

perform pujas or visit a place of worship during

reporting of side effects increased significantly in the

menstruation. Overall, half (52%) of all women—

period between the first and second doses, and fell

ranging from 40 percent of those experiencing

significantly thereafter, but experiences of individual

some menstrual disturbances to 65 percent of those

side effects varied considerably. For example, there

experiencing some other side effects—reported that

was a significant increase in the experience of

the side effect had interfered with the performance

weight gain, self-reported foul smelling vaginal

of their regular household responsibilities. Women

discharge and swelling of feet and hands between

who experienced both menstrual disturbances and

the first and second doses, which then levelled off or

other side effects and those who experienced three

declined marginally thereafter. At the same time, the

or more side effects, were most likely to report

experience of weakness and back pain increased more
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11.5
5.6
14.9
11.5
375

Weight loss

Foul smelling vaginal discharge

Anxiety/stress

Other (swelling/pain in feet/hands,
abdominal pain etc)

Number of women

237

11.0

17.7

4.6

15.6

13.1

44.7

36.3

30.8

11.0

26.6

29.7

52.2***

138

12.3

138

2.2

2.2

0.7

4.3***

0.7

5.8

19.6*

10.1**

9.4

7.2

7.2

22.2
29.7***

23.2

9.4

21.0**
53.6

3.6

8.0

10.9***
13.8

47.1

51.4

(5)

74.6

81.2

(4)

1st dose

138

5.8*

138

6.5

2.9

3.6
5.1

0.7
4.3**

11.6

13.0
0.7

12.3**

15.2

10.9

26.1*

33.3**
10.9

21.7

23.2

9.4

3.6*
9.4

2.9
8.7*

34.8

43.5

(7)

3rd dose

3.6**

39.1

50.0

(6)

2nd dose

Among women who took at least three doses of
injectable contraceptives, those who experienced a
side effect after each doseb

Note: Multiple responses possible; aIndependent samples t-test showing the difference in complications experienced between the two groups; bPaired t-test between 1st versus
2nd and 2nd versus 3rd doses; *p<=0.10, **p<=0.05, ***p<=0.01.

15.5

Weight gain

29.5

57.6

Other
26.9

42.1

Amenorrhoea

39.7

27.2

Irregular periods

Backache

12.0

Spotting between menstrual periods

Weakness

59.9

20.8

Heavy bleeding

81.9
76.4

81.6
75.7

Experienced one or more side effects

(3)

Menstrual disturbances

(2)

(1)

Side effects experienced

All women who
Women who
Women who
had adopted
discontinued
continued up to
injectable
after one or two three or more
contraceptives
doses
doses

Among all women, those who experienced a side
effect at any time during injectable contraceptive usea

Side effects experienced: Percentage of women by types of side effects experienced after each dose of the injectable contraceptive

Table 3.6

Injectable contraceptives: Perspectives and experiences of women and health care providers in India

Chapter 3: Experiences of women using injectable contraceptives

Table 3.7

Of women experiencing at least one side effect, percentages reporting that they had complained
to a health care provider about the side effect and that the side effect had affected their ability to
perform household work
Women who had
complained to a health
care provider about the
side effect

Women whose side
effect affected the
performance of
regular household
responsibilities

Number of injectable
contraceptive users who
experienced the side
effect

Any side effect

62.4

52.3

306

Any menstrual disturbance

58.8

40.1

284

Side effect(s) experienced

Any other side effect (other than
menstrual disturbance)

59.7

64.8

216

One or two side effects

43.9

26.8

164

Three or more side effects

83.8

81.7

142

Only menstrual disturbances, no
other side effects

32.2

16.7

90

Only other side effects, no
menstrual disturbances

27.3

36.4

22

Both menstrual disturbances and
other side effects

80.4

70.6

194

Specific side effects

Note: Multiple responses possible.

that the performance of their regular household

months prior to the interview; a few women were

responsibilities had been affected. For example,

included whose first dose of injectable contraceptives

71 percent of those who experienced menstrual

had been taken earlier, that is, 16–21 months prior

disturbances along with other side effects (most often

to the interview. About one half of all women

backache, weakness and weight gain), and 82 percent

reported that they had taken just one dose of

of those who experienced three or more side effects,

injectable contraceptives, and just one quarter

reported that the side effect had disturbed their

reported taking four or more doses.

performance of household responsibilities, compared

Life table method continuation rates were

to 17 percent of those who had experienced a

measured at the completion of the second, third,

menstrual problem without other side effects and

fourth and fifth doses, that is at six, nine, 12 and

36 percent of the small number of women who

15 months, respectively, and are presented in

had experienced some other side effect without any

Figure 3.1. Findings confirm low rates of

menstrual disturbances.

continuation. The continuation rate after six months

Method continuation

was just 51 percent, and fell to 37 percent, 23

The study recruited women who had adopted

respectively.

percent and 15 percent at nine, 12 and 15 months,

injectable contraceptives for the most part, 12–15
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Figure 3.1 Life table continuation rates of injectable contraceptives at the completion of each
tri-monthly dose

Note: Eleven women who returned for a subsequent dose of injectable contraceptives three or more months after the scheduled appointment
for re-injection, have been treated as having discontinued the method.

Use failure

all users (53%) reported that they had discontinued
using injectable contraceptives because of irregular

In one case, the woman reported that she was late

menstruation, heavy bleeding or amenorrhoea

for her re-injection and had become pregnant during

associated with method use. In addition, some 37

this period, thus giving a typical use failure rate of

percent reported such other side effects as vaginal

0.3 percent.

discharge, swelling of hands and feet, itching, pain
and weight gain. The second most often cited cluster

Reasons for discontinuation

of reasons for discontinuation was method-related:

The 329 women who had discontinued the use of

some 20 percent reported that they had planned

injectable contraceptives any time up to the time of

to switch to another method, did not like the

the interview were probed about their reasons for

method, had doubts about it, needed a break from

discontinuation. Findings, presented in Table 3.8,

it or that the method was not convenient to use. A

suggest that, as observed in previous studies, the

third group of reasons were access-related, centring

reasons for discontinuation centred largely around

around difficulties in accessing supplies: 16 percent

the side effects experienced. Some 65 percent of

cited these reasons, mostly concerning difficulties in

all those who had discontinued the method cited

reaching the facility to obtain subsequent doses of

a health-related reason for doing so. The leading

injectable contraceptives. Finally, some 10 percent

side effect, again as noted in other studies, was

of those who had discontinued cited fertility-related

menstrual disturbances. In total, more than half of

reasons: in order to become pregnant or because they
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Table 3.8

Factors underlying discontinuation: Percentage of women who discontinued use of injectable
contraceptives by dose after which the method was discontinued and reason(s) for discontinuation

Reasons for discontinuation

All women
who had
discontinued
injectable
contraceptive
use

Women who discontinued injectable
contraceptive use by dose after which the
method was discontinued
1st
dose

2nd
dose

3rd
dose

4th–8th
doses

Health-related reasons

65.0

70.5

59.3

62.7

51.2

a. Menstrual disturbances

52.6

61.7

35.2

49.0

39.0

Irregular menstruation

18.5

21.3

16.7

13.7

14.6

Heavy bleeding

18.8

25.7

11.1

9.8

9.8

Amenorrhoea

24.3

25.7

13.0

35.3

19.5

b. Other

37.4

38.8

42.6

33.3

29.3

Negative effect on health (includes infection, white
discharge, swelling in hands and feet, itching,
abdominal pain, weight gain)

37.4

38.8

42.6

33.3

29.3

Method-related reasons

20.4

19.7

14.8

17.6

34.1

Planned to switch to another method

9.4

9.3

3.7

5.9

22.0

Did not like the method

3.6

4.4

3.7

0.0

4.9

Not convinced/Had doubts about injectable
contraceptives

8.2

8.2

7.4

11.8

4.9

Needed a break from injectable contraceptive use

1.2

0.0

0.0

2.0

7.3

Method not convenient to use

0.3

0.0

1.9

0.0

0.0

Access-related reasons

16.1

13.7

27.8

15.7

12.2

Difficulty in reaching the facility

13.4

12.0

20.4

13.7

9.8

High cost of injectables

1.8

1.6

3.7

0.0

2.4

Health care provider not easily accessible

0.6

0.0

1.9

2.0

0.0

Injectable contraceptives were not available at the
clinic

0.9

0.5

3.7

0.0

0.0

10.3

10.4

7.4

13.7

9.8

Planning a pregnancy

Fertility–related reasons

4.9

3.8

3.7

5.9

9.8

Not having sex/Infrequent sex/Husband away

5.2

6.6

1.9

7.8

0.0

Menopausal/Had a hysterectomy

0.6

0.0

1.9

2.0

0.0

Use failure

0.3

0.5

0.0

0.0

0.0

329

183

54

51

41

Number of discontinuers
Note: Multiple responses possible.
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were infecund or not engaging in sexual relations

typically cited by fewer women and do not show

regularly. As noted above, one woman reported use

a consistent pattern over the period of use. For

failure as a reason for discontinuation.

example, method-related reasons were cited by
15–20 percent among those who discontinued

What is notable is that irrespective of the

after the first, second and third doses, respectively,

duration of use of injectable contraceptives,

but increased to 34 percent thereafter. Fertility-

menstrual disturbances remain the leading reason

related reasons ranged from 14 percent to seven

that women attributed to discontinuation of the

percent, while access-related reasons increased

method. At the same time, there is an inverse

from 14 percent to 28 percent among those who

association between duration of use and reported

discontinued the method after the first and second

discontinuation attributed to menstrual disturbances:

doses, and fell to 12 percent among those who did

from 62 percent after the first dose to 39 percent

so after the fourth or subsequent dose.

after the fourth or subsequent dose. Other reasons
for discontinuation did not vary as widely. For

Figure 3.2 shows life-table continuation rates

example, other side effects were reported to have

among women who had adopted injectable

influenced discontinuation for 39 percent of users

contraceptives, by side effects experienced: notably,

who discontinued after the first dose, as compared

any side effect, menstrual disturbances without any

to 29 percent of those who discontinued after the

other side effect, and both menstrual disturbances

fourth or subsequent dose. Other reasons were

and some other side effect (small numbers prevented

Figure 3.2 Life table continuation rates of injectable contraceptives at the completion of each
tri-monthly dose by side effects experienced
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us from conducting the same exercise among

month 12; 22 percent and 10 percent, respectively,

those who experienced only other side effects).

at month 15; and 18 percent and 6 percent,

Continuation rates were largely similar up to six

respectively, at month 18.

months of method use. Thereafter, differences

Method switching

emerged. Continuation rates were somewhat higher
among those who experienced only menstrual

A large proportion of women who had discontinued

disturbances than among those who experienced

the use of injectable contraceptives switched to a

both menstrual disturbances and other side effects.

different method, as evident from Table 3.9. Almost

For example, at nine months, 42 percent of those

one-third (31%) of discontinuers had switched

experiencing only menstrual disturbances had

directly to a terminal (5%) or other non-terminal

continued using the method compared to 34 percent

(26%) method, and another 29 percent had

of those experiencing both menstrual disturbances

discontinued contraceptive use entirely for more

and other side effects; corresponding percentages

than one month, but adopted a terminal (7%) or

were 27 percent and 18 percent, respectively, at
Table 3.9

Of women who discontinued use of injectable contraceptives, percentages who had switched
methods immediately and after a break of one or more months, by method adopted
Women who discontinued
injectable contraceptive use

Contraceptive status of discontinuers
Discontinued and did not use any contraception

40.4

Discontinued and switched immediately (within a month) to

30.7

Oral contraceptive pills

8.2

Intrauterine contraceptive device

1.8

Condom

11.9

Female sterilisation

4.9

Periodic abstinence

3.0

Withdrawal

0.9

Discontinued and switched later (between one and three months) to

28.9

Injectable contraceptives

3.3

Oral contraceptive pills

7.0

Intrauterine contraceptive device

1.2

Condom

6.4

Female sterilisation

7.0

Periodic abstinence

3.3

Withdrawal

0.6

Number of discontinuers

329
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other non-terminal (22%) method thereafter. Indeed,

continuation rate was 65 percent; corresponding

three percent of discontinuers opted to return to

percentages at 12 months were 23 percent and 45

the method after a one- to three-month break.

percent, respectively. We also calculated an all-

Overall, however, 40 percent of women who had

method continuation rate that also includes women

discontinued method use had not adopted another

who discontinued injectable contraceptive use for a

method until the date of the interview; as many as

period of one to three months and then switched to

10 percent had deliberately discontinued method use

another method (without becoming pregnant during

in order to become pregnant, because they were no

these months); with this definition, the all-method

longer at risk of pregnancy, or because they were not

continuation rates were 71 percent and 53 percent at

having regular relations with their husband.

six and 12 months, respectively.

Given the above profile of method switching,

Acceptability of injectable
contraceptives

we explored all-method continuation rates (Figure
3.3). In view of the fact that many women switched
from injectable contraceptives to another method

In order to assess the perceptions of injectable

without a break, the all-method continuation rate

contraceptive users about the method, we asked

is considerably higher than the continuation rate

them to list the positive and negative features of the

of injectable contraceptives. For example, compared

method. As seen in Table 3.10, about three quarters

to a six-month continuation rate of 51 percent

of all women identified at least one positive feature.

for injectable contraceptive use, the all-method

Large proportions of women reported, among its

Figure 3.3 Life table all-method contraceptive continuation rates among women who had adopted
injectable contraceptives
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Table 3.10

Perceived features of injectable contraceptives among all women by duration of injectable
contraceptive use

All women

Women who
discontinued
injectable
contraceptive use
within 12 months
(three or fewer doses)
(%)

Safety

18.9

16.0

28.7***

Enables women to effectively control
their fertility

38.1

32.6

56.3***

Long-acting, does not require a daily
routine

34.9

31.3

47.1***

Easy to use

23.7

18.8

40.2***

Reversible

1.3

0.7

3.5**

Can be used confidentially

5.9

6.6

3.5

At least one positive feature

75.2

70.1

91.9***

17.6

20.8

6.9***

4.0

3.8

4.6

Irregular periods

20.8

22.6

14.9*

Amenorrhoea

33.3

34.7

28.7

Backache

6.7

6.6

6.9

Weakness

23.2

25.4

16.1*

Weight gain

12.5

10.4

19.5**

Perceived features of injectable
contraceptives

Women who
continued injectable
contraceptive use for
12 or more months
(at least four doses)
(%)

Positive features

Negative featuresa
Heavy bleeding
Spotting between menstrual periods

Weight loss

1.3

1.7

0.0

Foul-smelling vaginal discharge

1.6

1.4

2.3

Inconvenient to use

0.8

0.7

1.2

Cost

0.8

1.0

0.0

Difficult to obtain repeat doses

2.1

2.8

0.0

Stomach pain/heaviness

2.1

1.4

4.6*

Body/leg/knee/breast pain and
breathing problems

3.2

3.5

2.3

Itchiness

0.5

0.7

0.0

72.8

77.8

56.3***

375

288

87

At least one negative feature
Number of women

Note: Multiple responses possible; a0.3 percent reported other reasons, not included in the table; *p<=0.10,
***p<=0.01.
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positive features, that it enabled women to control

amenorrhoea as a negative feature of injectable

their fertility (38%), that it was long-acting and does

contraceptives (35% and 29%, respectively), and

not require a daily routine (35%), that it is easy

weight gain was significantly more likely to be

to use (24%) and that it is safe (19%). Although

reported by those who had continued using the

many women identified the positive features of

method for at least 12 months than those who had

injectable contraceptives, almost as many women

used it for shorter periods of time (20% versus 10%).

(73%) identified at least one negative feature of

Additionally, we asked injectable contraceptive

injectable contraceptives. Among its negative features,

users who had also used the IUCD and oral

as expected, were the menstrual disturbances it

contraceptive pills, respectively, about their preferred

causes: 33 percent reported amenorrhoea, 21 percent

method and the reason(s) for such preference

reported irregular periods and 18 percent reported

(not shown in table). Among the 39 injectable

heavy bleeding as its worst feature. Other negative

contraceptive users who had also used an IUCD

aspects included weakness, reported by almost one in

either before adopting or after discontinuing

four women (23%) and weight gain, reported by 13

injectable contraceptives, 72 percent (28 women)

percent of the women.

said that they preferred injectable contraceptives.

As expected, women who had discontinued the

Leading reasons for this preference included that it

method before completing 12 months of use (three

was safer (57%) and easier to use (57%). Eleven

doses or fewer) were more likely than those who

injectable contraceptive users, who expressed a

had continued using the method for 12 months or

preference for the IUCD, also said that the IUCD

more (at least four doses) to report negative features.

was safer (6) and easier (1) to use; other reasons

For example, 30 percent of the former group,

included the fact that it is longer-acting (3) and

compared to eight percent of the latter group could

reversible (3).

not identify a single positive feature of injectable

Among the 92 injectable contraceptive users who

contraceptives; conversely, while 22 percent of those

had also used oral contraceptives at some point

who had discontinued the method before completing

in their contraceptive careers, 53 percent reported

12 months of use reported that the method did not

that they preferred injectable contraceptives because

have any negative features, as many as 44 percent of

they are long–acting, do not require a daily routine

those who had continued for at least 12 months so

(78%) and were perceived to be safer (29%). Of the

reported. Women who continued using the method

43 women who preferred oral contraceptives, reasons

for at least 12 months were significantly more likely

for this preference included the perception that oral

to report such positive features as its safety and

contraceptives are safer (63%) and easier (42%) to

effectiveness, and its long-acting nature and ease

use, do not cause amenorrhoea (19%), are more

of use than were those who discontinued before

effective (9%), are reversible (9%), and allow women

completing 12 months of use. Conversely, those who

to control their own fertility confidentially (16%).

discontinued before completing 12 months of use
were significantly more likely than those who had

Factors influencing injectable
contraceptive continuation

continued using it for at least 12 months to report
such negative features as heavy bleeding, irregular
periods and weakness. What is notable is that large

Multivariate analysis was conducted to explore

and similar proportions of both groups reported

factors, both socio-demographic and use-related,

28

29

Note:

*p<=0.10, **p<=0.05, ***p<=0.01.

Number of women

Constant
–2 LL

Use–related factors
Health care provider said that the method they intended to
use was inappropriate (No=ref )
Decision to adopt injectable contraceptives taken by both
husband and wife (No=ref )
Quality of care: Health care provider answered all questions
regarding injectable contraceptives satisfactorily (No=ref )
Experience of side effects (None=ref )
Experienced menstrual disturbances only
Experienced other side effects only
Experienced both menstrual disturbances and other side
effects

Socio-demographic factors
Age (continuous)
Education (continuous)
Religion: Muslim (Hindu=ref )
Scheduled caste/tribe or other castes (General=ref )
Family type: Living with husband and children (No=ref )
Work status: Working at the time of first dose (No=ref )
Household standard of living index
Total number of children at the time of first dose
Residence: Large urban area (No=ref )

(1)

Factors influencing method continuation

(0.88–1.01)*
(1.02–1.18)**
(0.45–2.18)
(0.84–2.87)
(0.58–1.70)
(0.39–1.48)
(0.87–1.08)
(1.05–1.80)**
(0.90–3.30)

0.37 (0.21–0.66)***

0.20 (0.12–0.35)***

375

375

0.21
452.3

0.67 (0.36–1.26)
0.52 (0.18–1.49)

0.58 (0.32–1.06)*
1.10 (0.35–3.44)

1.14
461.2

1.73 (1.01–2.98)**

1.74 (1.08–2.78)**

1.33 (0.83–2.12)

375

0.38
371.0

0.38 (0.19–0.73)***

0.69 (0.34–1.37)
0.65 (0.19–2.18)

1.26 (0.74–2.15)

1.81 (0.75–4.35)

0.94
1.10
0.99
1.55
1.01
0.76
0.97
1.37
1.72

1.75 ( 1.10–2.79)**

(0.94–1.06)
(0.99–1.11)
(0.68–2.60)
(0.93–2.70)*
(0.88–2.67)
(0.43–1.32)
(0.91–1.11)
(0.81–1.29)
(0.82–2.55)

1.57 (1.00–2.47)**

1.00
1.05
1.32
1.59
1.42
0.75
1.01
1.02
1.44

(4)

Women who continued for
4 or more doses compared
to those who discontinued
earlier

1.19 (0.52–2.74)

(0.92–1.04)
(0.98–1.10)
(0.58–2.20)
(0.67–1.87)
(0.99–2.53)*
(0.63–1.90)
(0.90–1.09)
(0.88–1.37)
(0.76–2.35)

(3)

Women who continued for
3 or more doses (at least 9
months) compared to those
who discontinued earlier

1.24 (0.54–2.83)

0.98
1.04
1.13
1.12
1.58
1.09
0.99
1.10
1.34

(2)

Women who continued for
2 or more doses (at least 6
months) compared to those
who discontinued earlier

Factors influencing method continuation: Logistic regression, odds ratios (95% confidence intervals)
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influencing the continuation of injectable

who had reported joint decision-making and lower

contraceptive use. Findings, presented in Table 3.11,

among those who experienced menstrual and other

compare women who discontinued use of injectable

side effects; the odds were also greater among those

contraceptives after the first dose with those who

who reported good quality of care as compared with

continued for two or more doses (Column 2), those

other women. This general picture was evident also

who discontinued use of injectable contraceptives

among women who had continued to use injectable

after the first or second dose with those who

contraceptives for 12 or more months compared

continued for three or more doses (Column 3),

to other women, except that joint decision-making

and those who discontinued use of injectable

was no longer significant in influencing method

contraceptives after one to three doses with those

continuation.

who continued for four or more doses (Column 4).

Summary

Findings suggest that continuation was associated
with a number of socio-demographic and use-

Findings suggest that women obtained information

related factors. As far as socio-demographic factors

about injectable contraception largely from health

are concerned, for example, findings show that the

care providers, but also from family and friends.

odds that a woman had continued to use injectable

Irrespective of the source of information, about

contraceptives for at least six or nine months were

two-thirds of women who had adopted injectable

unrelated with most socio-demographic variables. In

contraception had made the decision to do so

contrast, the odds that a woman had continued to

themselves, either on their own or together with

use injectable contraceptives for at least 12 months

their husband.

or four doses were greater among younger and better

Injectable contraceptive related counselling was

educated women, and those with larger numbers

somewhat incomplete. While almost all the women

of children at the time of adopting injectable

had been informed about the need for three-monthly

contraceptives as compared to other women.

re-injections and their cost, and most had been
informed about how the method works and the fact

Among use-related factors, the odds that a woman
had continued to use injectable contraceptives

that it is a non-terminal method, fewer than half

for at least 6 months were greater among those

had been counselled about possible side effects, what

who reported that the decision to use injectable

to do if side effects were encountered, and the need

contraceptives was made by both the woman and

to return to the service provider or facility in case of

her husband, and were much lower among women

doubts about the method or if any side effects were

who experienced menstrual disturbances only or

experienced.

both menstrual disturbances and other side effects

As other studies have observed, more than four in

compared to other women. Notably, continuation

five women had experienced at least one side effect,

was not affected by the quality of care that is,

largely menstrual disturbances or backache, weakness

whether or not the health care provider had

and weight gain. However, among women who had

answered all their questions satisfactorily. In contrast,

continued using injectable contraceptives for three or

the odds that a woman had continued to use

more doses, a comparison of side effects experienced

injectable contraceptives for nine or more months

by women between doses suggested that while the

were greater, as in the earlier case, among women
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experience of menstrual disturbances, and notably

injectable contraceptive use was evident from

amenorrhoea, declined marginally between doses,

findings suggesting that life table continuation

heavy bleeding fell significantly between the first

rates were considerably lower among women who

and second doses. Experience of other side effects,

experienced both menstrual disturbances and other

in contrast, and notably weight gain, increased

side effects than among those who experienced just

in the period between the first and second doses,

menstrual disturbances.

and levelled off thereafter, while the experience of

Following discontinuation of injectable

weakness and back pain increased more modestly

contraceptive use, about three in ten women

between the first and second doses, and also levelled

switched immediately to another contraceptive

off thereafter. In all, about three-fifths of all women

method; a similar proportion switched to another

who experienced a side effect had complained

method (including those who switched back to

about it to a health care provider and about one

injectable contraceptives) after a gap of one to three

half noted that the side effect had affected their

months, and about two in five women did not

ability to perform their household responsibilities.

adopt another method even after a three month

Indeed, women who had experienced three or more

gap. All-method continuation rates suggest that

side effects were more likely than other women to

by 12 months of the initial adoption of injectable

so report; women who had experienced menstrual

contraceptives, as many as 45 percent continued to

disturbances were, on average, less likely to have

be protected by one or other contraceptive method.

complained and less likely to have reported that the

All-method continuation rates that include those

side effect had affected their ability to perform their

who had discontinued contraception for a period of

household responsibilities than were those who had

one to three months (but had not become pregnant)

experienced other side effects.

before switching to another method, suggest an

Life table continuation rates suggest that many

all-method continuation rate of 53 percent at 12

women discontinued using injectable contraceptives

months.

after the first injection, and by 12 months, just 23

Overall, women were divided about the

percent were continuing to use the method. Reasons

acceptability of injectable contraceptives. As many as

for discontinuation centred largely around the side

one quarter of all women could not identify a single

effects experienced, with two-thirds of all those who

positive feature, and a slightly larger proportion

had discontinued injectable contraceptive use citing a

could not identify a single negative feature of

health-related factor, largely menstrual disturbances,

injectable contraceptives. Key positive features

as the reason. Many fewer cited method-related

included that it enables women to control their

reasons (that they planned to switch to another

fertility, that it is long-acting and does not require

method, did not like the method, had doubts

a daily routine, that it is easy to use and that it is

about it, needed a break from it, or that it was

safe. Key negative features, as expected, were the

inconvenient to use), reasons related to difficulties in

menstrual disturbances and other health-related side

accessing supplies, and fertility-related reasons (that

effects caused by injectable contraceptives. Women

they wanted to become pregnant, were infecund or

who had discontinued the method before completing

did not engage in sexual relations regularly). That

12 months of use (three doses or fewer) were more

side effects were a central reason for discontinuing

likely than those who had continued using the
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method for 12 months or more (at least four doses)

associated with a number of socio-demographic and

to report its negative features and correspondingly,

use-related factors. The odds that a woman had

were significantly more likely to report such positive

continued to use injectable contraceptives for at

features as its safety and effectiveness, its long-

least 12 months, for example, were greater among

acting nature and ease of use than were those who

younger and better educated women, and those with

had discontinued before completing 12 months

larger numbers of children at the time of taking the

of use. Over one half of women who had used

first dose of injectable contraceptives as compared

injectable contraceptives as well as the IUCD or oral

to other women; the odds were greater among

contraceptive pills (prior to adoption of injectable

those who had received good quality of care and

contraceptives or post discontinuation) reported

lower among those who had experienced menstrual

that they preferred to use injectable contraceptives.

disturbances along with other side effects. Some

Leading reasons for this preference included its

notable differences appeared to mark discontinuation

perceived safety, ease of use, long-acting nature and,

earlier than 12 months. For example, joint decision-

in comparison to oral contraceptive pills, that it did

making with the husband was an important correlate

not require a daily routine.

of continuation beyond three and six months but
did not remain significant thereafter; and quality of

Continuation of injectable contraceptive use,

care was unrelated with continuation beyond three

as assessed by multivariate analysis, was largely

months but became significant thereafter.
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Perspectives on injectable contraceptives
among women seeking to adopt contraception
A secondary objective of this study was to assess

to adopt contraception in study facilities were

the extent to which new method adopters opted for

interviewed.

injectable contraceptives and their motivations for

Pre-adoption counselling

adopting the method selected. A survey, comprising
exit interviews, was conducted among women

Descriptions of pre-adoption counselling suggest

seeking to adopt a contraceptive method from the

that injectable contraceptives were included among

facilities from which our sample of women who

the basket of contraceptives offered to just one

had earlier adopted injectable contraceptives was

quarter (24%) of women seeking contraception, as

drawn. Interviewers spent two to three days in each

seen in Table 4.1. Of the 28 women who reported

facility and interviewed all consenting women who

that the health care provider had indeed discussed

sought to adopt contraceptive services on those days.

injectable contraceptives with them, the kinds of

The interviews aimed to explore two main issues:

issues addressed resemble those described by women

the extent to which pre-adoption counselling had

who had adopted injectable contraceptives in March

included injectable contraceptives among the range

to September, 2010. For example, all women were

of contraceptives described to the woman and the

informed that they would have to return to the

kind of information about injectable contraceptives

facility every three months to repeat the dose of

provided; and the method finally adopted and

injectable contraceptives and 82 percent were told

reasons for adopting or not adopting injectable

the advantages of using the method. However,

contraceptives. A total of 117 women seeking

considerably fewer reported that the health care

Table 4.1

Percentage of women seeking to adopt contraception by pre-adoption counselling received
Women seeking to
adopt contraception

Content of pre-adoption counselling
Health care provider talked about injectable contraceptives
Among those to whom the health care provider talked about injectable
contraceptives
Told about the advantages of using injectable contraceptives
Told about the three month follow-up visit for repeating injections

23.9
(N=117)
N=28
82.1
100.0

Told about the cost of each injection

57.1

Told about the possible side effects of injectable contraceptives

46.4
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provider had informed them about the cost of each

contraceptives may reflect the fact that the NGO

dose of injectable contraceptives (57%), and fewer

facilities in which the study was located were well-

than half (46%) reported receiving information

known for offering injectable contraceptives; and

about the possible side effects of the method.

hence their clientele may not be representative of
all women seeking to adopt contraception more

Method adopted

generally. Aside from those who had a method in
mind when they visited the facility, 11 percent

The large majority of women reported that they

reported that they had been undecided about which

had decided the method they wished to adopt prior

method to adopt when they visited the facility.

to attending the facility. As evident from Table 4.2,
the majority (62%) had planned to adopt and had

Most women, 95 of the 104 who had a

indeed adopted female sterilisation (60%). Others

particular method in mind (91%), had adopted

had opted for non-terminal methods: 15 percent

the method they had intended to adopt. Of the 13

for the IUCD, five percent for oral contraceptives

women who were undecided about which method

and four percent for injectable contraceptives. In

to adopt, two opted for tubal ligation, seven for

short, one-sixth of all women who had a specific

oral contraceptives, two for condoms, and two for

non-terminal method in mind had planned to adopt

injectable contraceptives. Of the eight women who

injectable contraceptives and one-fifth (10 of 47)

had planned to adopt a particular method and

of those who adopted a non-terminal method had

adopted a different method, five, two and one,

opted for injectable contraceptives. We acknowledge

respectively, had intended to adopt tubal ligation,

that this large proportion opting for injectable

the IUCD and oral contraceptive pills, but none of

Table 4.2

Percentage of women seeking to adopt contraception by contraceptive method they intended to
adopt and the method adopted
All women
Method the woman
intended to adopt

Method adopted by
the woman

0.9

0.9

Female sterilisation

62.4

59.8

Iintrauterine contraceptive device

14.5

12.8*

Oral contraceptive pills

5.1

14.5

Condom

1.7

3.4

Injectable contraceptives

4.3

8.5

No method planned

11.1

**

Number of women

117

117

Method
Male sterilisation

Note: *Includes one woman who was provided the emergency contraceptive pill and asked to return in two weeks to have the
IUCD inserted; **Includes 13 women who adopted tubal ligation(2), oral contraceptive pills(7), condoms(2) and injectable
contraceptives(2).
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these women obtained the method she had originally

many as 62 percent reported that they and their

decided upon; instead, the methods adopted were

husbands, they alone (18%) and their husband alone

oral contraceptives (five women) and injectable

(13%) had made the final decision. Some 21 percent

contraceptives (three women). Most women who had

reported the involvement of a health care provider

not adopted their intended method reported that

and nine percent of their mother-in-law. It is notable

the health care provider had dissuaded them from

that one-fifth of all women were excluded from the

adopting that method, indicating that it would not

final decision on which method to adopt (not shown

be appropriate in their situation (further details were

in table).

not probed).

Method preferences

In short, a comparison of the method women
intended to adopt and the method actually adopted

Exit interviews explored the reasons that the 107

suggests a shift away from terminal to non-terminal

women who had adopted methods aside from

methods, and towards such non-terminal methods as

injectable contraceptives gave for not adopting this

oral and injectable contraceptives.

method. As shown in Table 4.3, the large majority—
as many as two-thirds—reported lack of awareness

Decision-making with regard to the method

of injectable contraceptives. A second leading

finally adopted suggests that 80 percent of all

factor dissuading women from adopting injectable

women had made the final decision about which

contraceptives was the fear of side effects (18%).

method to adopt on their own or together with their

Other concerns included difficulty in accessing the

husband, mother-in-law or health care provider. As

facility for repeat doses (9%), high cost of repeat

Table 4.3

Reasons for non-adoption of injectable contraceptives

Reasons given for non-adoption of
injectable contraceptives

Women who adopted
all methods other
than injectable
contraceptives
(%)

Number of women
who adopted
the IUCD
(n)

Number of women
who adopted oral
contraceptives
(n)

Not aware of injectable
contraceptives

65.4

8

8

Fear of side effects of injectable
contraceptives

17.8

4

3

9.3

2

2

Difficulty in accessing the facility for
repeat doses
Husband disapproves of injectable
contraceptives

7.5

1

1

Cost of repeat doses

2.8

0

1

Preference for tubal ligation

0.9

0

0

Health care provider dissuaded
injectable contraceptive use

3.7

1

2

107

14

17

Number of women
Note: Multiple responses possible.
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doses (3%), husband’s disapproval of the method

women seeking contraception and about one-fifth

(8%) and preference for tubal ligation (1%). In

of those who opted for a non-terminal method at

addition, four percent of women reported that

study facilities had adopted injectable contraceptives.

the health care provider had dissuaded them from

Findings suggest a number of factors underlying

adopting injectable contraceptives.

the relatively limited adoption of this method.
Many women were unaware of the method.

A roughly similar picture emerges when we

Indeed, two-thirds of those who had adopted other

explore the reasons that women who adopted the

methods reported that they were unaware of the

IUCD and oral contraceptives gave for preferring

availability of injectable contraceptives. As most

these methods to injectable contraceptives. While

women had adopted the method they had intended

numbers are small, it is clear that the potential side

to adopt prior to visiting the facility on the day

effects of injectable contraceptives are a significant

of the interview, this lack of general awareness is

deterrent. So too were difficulties associated with

likely a key factor inhibiting the use of injectable

accessing the facility for repeat doses of injectable

contraceptives. At the same time, information was

contraceptives, even compared to oral contraceptives

unlikely to be provided at the facility: few women,

which could be accessed from a number of outlets

just one in four, were informed about the availability

closer to the woman’s home and did not require a

of injectable contraceptives during pre-adoption

return visit to the facility.

counselling by the health care provider.

Women who had adopted injectable contraceptives

Further insights come from women who

highlighted a number of advantages of the method

had adopted methods other than injectable

over oral contraceptive pills, for example. Of the 10

contraceptives. For example, fear of side effects

women who had adopted injectable contraceptives,

was clearly a major factor inhibiting the adoption

five reported that a key advantage over oral

of injectable contraceptives. The cost of injectable

contraceptives was that it is long-acting and does not

contraceptive repeat doses was an inhibiting factor

require a daily routine; five also reported that it is

for a few women who adopted oral contraceptive

“easier” to use; three reported that it offered women

pills and the IUCD. Moreover, the need to

greater confidentiality; and two mentioned that it

access the facility for repeat doses of injectable

is a highly effective method. Not a single woman

contraceptives was perceived as a serious disadvantage

reported that the method had fewer side effects (not

by many who regarded the IUCD, in comparision,

shown in table).

as a method not requiring repeated follow-up and

Summary

oral contraceptives, as one that could be purchased

Exit interviews with women seeking to adopt

home.

or obtained from facilities and outlets closer to

contraception revealed that just nine percent of
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Perspectives of health care providers on
injectable contraceptives
Health care provider perceptions about
method preferences of clients

The study also sought to obtain the perspectives of
health care providers on a number of issues relating
to the use of injectable contraceptives. Interviews

Health care providers were asked to estimate the

addressed, for example, health care providers’ own

number of women to whom they had provided

experience of providing injectable contraceptives:

injectable contraceptives in the year and month

the number of clients to whom they had supplied

preceding the interview. A range of responses were

injectable contraceptives, the type of counselling

received, for example, from ‘20–40’ to ‘about 1000’

provided to users and potential users, and provider

in the year preceding the interview, and from ‘2–3’

biases, if any, in terms of which type of client

to ‘20–30’ in the month preceding it. A few health

should be offered or should be denied injectable

care providers stated that large numbers of women

contraceptives. They were also probed about the

sought tubal ligation:

experiences of their clients who had used injectable
contraceptives, and specifically, their clients’ prior

Very few come for other contraceptives; the

awareness about the method, continuation, side

maximum number of clients come for sterilisation

effects experienced, follow-up and acceptability.

as it is a permanent method. They don’t have

Finally, they were asked for their opinion about the

much interest in temporary methods as they have

possible inclusion of injectable contraceptives in the

many things (doubts) in their mind regarding the

national programme, and their recommendations, if

side effects of these methods. (Dr. B, age

any, about how the method should be rolled out.

group 40–49)

As mentioned earlier, a total of 16 health care

Most women accept sterilisation. (Dr. D, age

providers were interviewed, at least one from

group 30–39)

each participating NGO. All health care providers

Rural clients prefer a permanent method. Urban

indicated that the facility in which they worked

clients accept temporary methods; they use

offered a range of contraceptive services, including

injectables and the Cu-T (IUCD) as temporary

both terminal methods and injectable contraceptives,

methods. (Dr. K, age group 40–49)

and abortion services. A few also mentioned the
provision of antenatal and postpartum services,

Other health care providers discussed the demand

services related to sexually transmitted infections and

for non-terminal methods among women seeking

adolescent counselling.

contraception. Four health care providers said
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that the IUCD (Cu-T) was the most commonly

Women like to accept injectable contraceptives as

desired non-terminal method among women seeking

the method is easy to use; in comparison, they

contraception in their facilities. Health care providers

don’t like to accept the Cu-T because of the fear

indicated:

of infection and the insertion procedure.
(Dr. P, age group 50+)

Few clients use oral contraceptive pills. Mostly,
they use the Cu-T as a temporary method.

Health care provider perceptions about
the advantages and disadvantages of
injectable contraceptives

(Dr. J, age group 50+)
Mostly, women accept IUCDs. (Dr. C, age
group 50+)

Health care providers were mixed about their views

(Most women opt for the) Cu-T. (Dr. A, age

on the appropriateness of injectable contraceptives as

group 50+)

a viable method for their clientele. Almost all agreed
that it is a safe and effective method,:

Aside from sterilisation, most women accept the

The first advantage (of injectable contraceptives)

Cu-T. (Dr. M, age group 40–49)

is their low failure rate; second, the method is

However, several health care providers noted

good as there is no problem of taking it daily

women’s interest in injectable contraceptives:

as in the case of pills, and third, privacy can be
maintained. (Dr. G, age group 50+)

They use two methods, the Cu-T first, and
next, they prefer injectables. (Dr. H, age

It is a good method but there are side effects.

group 30–39)

(Dr. A, age group 50+)

Mostly, women accept oral contraceptives; there

Injectable contraceptives are a very good, effective

are some misconceptions about the Cu-T...

and safe method, provided proper counselling is

Nowadays, many women have been showing a

given regarding side effects...it is not required

preference for injectables. (Dr. N, age

to be taken daily. Secondly, after a gap of three

group 40–49)

months, it is not absolutely necessary to take the

Some women (are interested); (because) injectable

next dose on a fixed date as its window period is

contraceptives have few side effects; pills give

also good. (Dr. L, age group 50+)

problems like nausea, vomiting etc. On the other

Injectable contraceptives are a confidential method;

hand, if the husband doesn’t wish to use Nirodh

privacy is maintained and it has to be taken only

(condom) or doesn’t use it properly, there are

once in three months. (Dr. P, age group 50+)

chances of the woman conceiving. Women feel
assured that with injectable contraceptives, they

As a temporary method for one or two years, it

will not conceive and that it has few side effects;

is a good method. However, if it is to be used

also, after proper counselling, their misconceptions,

for a longer period, it is important to know its

such as concerns about weakness, are reduced.

advantages and disadvantages. (Dr. K, age

(Dr. N, age group 40–49)

group 40–49)
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We prefer the Cu-T because if there is any

menstruate; she is afraid that she may be suffering

problem or it doesn’t suit the woman, we

from some disease. (Dr. C, age group 50+)

can remove it immediately, but if injectable

Side effects are not acceptable; women feel

contraceptives enter the body, we cannot do

disturbed if they experience amenorrhoea and

anything. Also, after discontinuing injectable

worry whether or not they are pregnant again.

contraceptives, the woman’s menses doesn’t return

(Dr. E, age group 30–39)

for six months to a year. (Dr. M, age
group 40–49)

Women who have bleeding-related problems, feel
uneasy; otherwise, they are happy. Fifty percent

At the same time, health care providers

discontinue the method because of amenorrhoea.

acknowledged that the method is associated with

(Dr. G, age group 50+)

many side effects and that these side effects made
injectable contraceptives an unattractive option for

I don’t find any drawback as such, but if

women. In fact, every single health care provider

amenorrhoea occurs as a side effect, then it is a

noted that menstrual disturbances are a major side

cause for concern. (Dr. N, age group 40–49)

effect of injectable contraceptives. Indeed, several

Irregular bleeding is a very big problem with

said that neither heavy bleeding nor amenorrhoea

injectables. It is a problem in our context because

were acceptable side effects for women. Health care

when a woman is bleeding, she is unable to

providers reported that many women who experience

worship God and it disturbs her psychologically;

these side effects express the fear of having a serious

so, women don’t wish to accept the method. The

disease and those who experience amenorrhoea

second problem is that if a woman experiences

fear that they are pregnant. Moreover, because of

irregular bleeding, we are unable to tell her when

cultural practices that forbid menstruating women

it will stop. Once injectables are used, the effect

from entering the kitchen or praying, heavy bleeding

of the drug remains for three months, and we

or irregular menstruation affected their ability to

can’t do anything about it. (Dr. O, age

perform these regular tasks:

group 40–49)

It is a good method, but there are side effects....

A number of health care providers also stated that

When it suits the woman, she is happy and takes

delayed resumption of menstruation and prolonged

three to four doses. But then, if a problem occurs,

time to conception following discontinuation of

she asks me, ‘What kind of injection have you

injectable contraceptives was a disadvantage especially

given me?’ (Dr. A, age group 50+)

for women intending to have another pregnancy

Not a very good method; it disturbs menstruation

on discontinuation of the method. They argued

greatly. Women come here in tension as they

that time to conception was far longer than that

have continuous bleeding or bleeding (menstrual

associated with the Cu-T or oral contraceptives, and

period) has completely stopped. (Dr. B, age

may not therefore be attractive to women seeking to

group 40–49)

space their births. For example:

It is a good method but it has many side effects

After removing the Cu-T, the woman can

like amenorrhoea. In such a situation, the client

conceive easily whereas it takes some time to

gets disturbed, thinking about why she does not

conceive after stopping injectables.... Women know
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that after stopping injectables, it will take one

injectable contraceptives, once fully informed.

year to conceive, so they stop after a few doses.

Leading obstacles included the inconvenience of

(Dr. H, age group 30–39)

returning to the facility every three months for reinjections, fear of side effects and cost. For example:

Some women are not able to conceive for many
days after they stop using injectable contraceptives.

Everyone asks about injectables, but they want a

(Dr. F, age group 40–49)

one-time injection: if we tell them that they will
have to come every three months, they are not

Sometimes, after stopping the injections, there

willing (to adopt the method). (Dr. C, age

is a delay in (the resumption of ) menses for six

group 50+)

months or a year. (Dr. A, age group 50+)

They don’t have much interest (in injectable

After stopping (discontinuing use), women

contraceptives) as they have many doubts in

are unable to conceive; they go into secondary

their mind about side effects. (Dr. B, age

infertility and have to undergo treatment for

group 40–49)

many days (for the resumption of menstruation).
(Dr. B, age group 40–49)

Mostly women prefer the Cu-T because once
inserted, they can be tension—free; they just have

After discontinuing injectable contraceptives, the

to pay Rs 50 once, whereas for injectables they

next pregnancy could be delayed; it is not so with

have to pay Rs 50 every three months.

other methods. The calcium level also goes down

(Dr. F, age group 40–49)

with the use of this method; this is not visible
but it could cause a problem. (Dr. K, age

Health care provider perceptions on
the appropriateness of injectable
contraceptives for different groups of
women

group 40–49)
If a client is newly married and does not have
even one child, we cannot give her injectables
because sometimes fertility is delayed, whereas

In the course of the in-depth interview, we made

after discontinuing the oral contraceptive pill,

efforts to gauge the perspectives of health care

pregnancy can happen soon. (Dr. L, age

providers about the appropriateness of injectable

group 50+)

contraceptives for women in India, including

Finally, we note that although injectable

whether health care providers would hesitate to offer

contraceptives are recommended for use in the

injectable contraceptives to poor or poorly educated

postpartum period and by lactating women (World

women.

Health Organization, 2010), this advantage was not

While almost all health care providers were in

specifically indicated by a single health care provider.

agreement that injectable contraceptives are a safe

Health care provider perceptions
about factors dissuading women from
adopting injectable contraceptives

and effective method, many acknowledged that it

Several health care providers also highlighted the

categories of women based on the woman’s age and

obstacles that dissuaded women from adopting

fertility intentions; for example, they would offer

is not an appropriate method for all women. For
example, several health care providers indicated that
they would recommend the method to only certain
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it to women who do not want another child, or to

We have to assess her family background,

older women, but would refrain from suggesting it to

her history, and do her physical screening. A

those who are newly married or to those who intend

particular method may not be suitable for

to have a child on discontinuation of the method.

certain clients, and even so, not for her entire
reproductive life. If a woman comes after delivery,

If the woman is young or newly married, I don’t

we prescribe the oral pill. We also need to see the

recommend the Cu-T generally, but condoms

age of her last child and which method she wishes

or oral pills are fine. On the other hand, if the

to adopt. (Dr. L, age group 50+)

woman is older and her family is complete, we

As regards offering injectable contraceptives

advise sterilisation. (Dr. E, age group 30–39)

to poor or poorly educated women, health care

If the client is newly married then we don’t

providers expressed divers views. A number of

recommend the Cu-T or injectable contraceptives

health care providers maintained that the extent to

as there are chances of infection with both these

which the client was educated did not affect their

methods, and if infection does occur, the entire

decision to offer injectable contraceptives to them.

blame is placed either on the provider or on the

For example, eight health care providers argued that

method. (Dr. P, age group 50+)

socioeconomic factors were unimportant:

If the client doesn’t even have one child, I do not

Her age, education or socioeconomic condition are

advise injectables. (Dr. J, age group 50+)

not significant. (Dr. B, age group 40–49)

We mostly recommend the Cu-T and injectables,

The client’s socioeconomic condition is not

but we prefer the Cu-T for women who may

significant. (Dr. D, age group 30–39)

want another child. (Dr. H, age group 30–39)

The woman’s socioeconomic condition is not

It is a good method, provided the woman’s family

significant. (Dr. G, age group 50+)

is complete and she is above 35 years. (Dr. I, age

Education is not significant; if everything is

group 30–39)

explained nicely, even illiterate women are able to

Age matters because at pre-menopausal ages,

understand everything. (Dr. F, age group 40–49)

hormonal methods of contraception should be

We provide information about each method, so

avoided. (Dr. O, age group 40–49)

education doesn’t matter much—but it matters for

A few health care providers described in detail

natural methods like the safe period etc.

the extent to which it was important to obtain the

(Dr. H, age group 30–39)

woman’s full history as there were certain health
conditions under which they would not recommend

Economic condition is not important; woman of

injectable contraceptives. For example:

all classes accept it (injectable contraceptives).
(Dr. I, age group 30–39)

Normally we do not advise injectables to a
woman who has a bleeding-related problem, a

Women, who are less educated or belong to

cyst in the ovaries, a problem in the cervix or a

a lower income group, accept it (injectable

cyst in the breast. So, we avoid giving injectables

contraceptives); they have more faith in the

to such women. (Dr. G, age group 50+)

doctor. (Dr. L, age group 50+)
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Economic conditions and educational

of the household did play a role in their decision to

qualifications are of no significance as most clients

offer the method to the woman. For example:

coming from rural areas are illiterate or have

Educational qualification is not significant... but

studied up to a maximum of 6th class only.

socioeconomic condition matters because for some

(Dr. M, age group 40–49)

methods, the charges are too high and poor clients

At the same time, eight other health care health

prefer to accept the cheapest method. (Dr. K, age

care providers affirmed that the poorly educated

group 40–49)

were less likely to comprehend the requirement of

Economic status is important to some extent

three-monthly injections and side effects associated

because if a woman needs to get a test done from

with injectable contraceptives. Four of these health

a private facility, and her economic condition

care providers suggested that they needed to spend

is not good, she will not be able to get her test

more time explaining the method to poor or poorly

done so easily. Injectables are not available in

educated women than others. For example:

government facilities either, so we can give the

If a woman is educated, she is able to understand

method to the client only if she can afford it.

(what she is told) about injectable contraceptives;

(Dr. N, age group 40–49)

we need to explain at length to village women.

Two others reported that they would recommend

(Dr. A, age group 50+)

other methods to a poorly educated woman. For

We can explain everything regarding injectable

example:

contraceptives and other methods properly to

Education is significant as educated women

educated women and they understand it. As

understand easily. They also understand the

compared to poorly educated women, educated

importance of follow up; to less educated women,

women understand injectable contraception better.

we suggest the use of condoms. (Dr. E, age

(Dr. C, age group 50+)

group 30–39)

Educational qualifications matter because we have

Yes, educational qualification is significant…. I

to explain more to a lesser educated client as only

recommend methods to women according to their

by doing so, we can follow up that client, which

needs and educational status. (Dr. J, age

is very important. (Dr. O, age group 40–49)

group 50+)

Yes, educational qualification is significant...

method. (Dr. P, age group 50+)

Injectable contraceptive related
counselling offered by health care
providers

The remaining four health care providers of this

Efforts were made to understand the kind of

group maintained that they would prefer to provide

counselling that health care providers offered

methods other than injectable contraceptives to poor

potential clients and specifically, whether they

or poorly educated women. Two reported that they

involved the husband in the counselling session and

would recommend injectable contraceptives to poorly

if they permitted clients to make the final decision

educated women, but that the economic condition

to adopt the method on her own.

educated women understand the method and
easily follow instructions about how to use the
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in the cervix or a cyst in the breast. So, we

For the most part, health care providers indicated
that counselling entailed the provision of such

avoid giving injectables to such women. First, I

information as the mechanics of the method (how

tell them that injectables are also a method of

often it must be taken) and the kind of side effects

contraception which is to be taken after every

that may occur. All health care providers indicated

three months and by taking which, the woman

that they informed women about such side effects

will not conceive. The second thing is that some

as amenorrhoea and heavy bleeding, and that the

women have a misconception that the injection is

woman should return to the clinic if she experiences

effective for three or five years; so, we clarify this

these side effects. However, although several health

too. Moreover, we also provide them information

care providers had also discussed weight gain as

about irregular bleeding and amenorrhoea as side

a disadvantage, not a single health care provider

effects of the method; due to this, although some

mentioned that they would inform the client about

women refuse to take injectables, most accept the

this side effect.

method. (Dr. G, age group 50+)

We tell them after how many days it (the

I take information about her menstrual history,

injection) is to be taken, about complications; we

menstruation-related problems and, at the same

tell them everything. (Dr. A, age group 50+)

time, information about whether or not she has
used any method previously and, if so, which

We inform them that this injection will function

method she has used and whether she had any

for three months only. We tell them about its side

problems using that method. If the woman is

effects etc. (Dr. C, age group 50+)

young or newly married, I don’t recommend the

We tell them that the monthly period may stop,

Cu-T generally, but condoms or oral pills are

bleeding may occur between periods, but there

fine. On the other hand, if the woman is older

is nothing to worry about. (Dr. D, age

and her family is complete, we advise sterilisation.

group 30–39)

I tell them about the side effects of the injection
such as amenorrhoea. If the woman is lactating,

We provide information regarding side effects like

I tell her that her milk may be reduced. At the

bleeding, stopping of menses (amenorrhoea) and,

same time, I advise her to take an injectable

at the same time, we also counsel them that there

dose after every three months. I also advise her to

is nothing to worry about. (Dr. M, age

come to the clinic in case of any side effect and

group 40–49)

assure her that there is nothing to worry and the
side effects, if any, can be cured with medicines.

Several health care providers narrated, in detail,

(Dr. E, age group 30–39)

the importance of gathering the woman’s complete
history; they also highlighted to their clients

We need to know the client’s complete history:

the mechanics of the method and the potential

whether she has any infection or any other

menstrual disturbances that could arise. For example:

problem. Most of our clients don’t have such

We counsel all women about injectable

problems; hence, we don’t discuss all these things

contraceptives but normally we do not advise

with all our clients... First of all, I provide

injectables to a woman who has a bleeding-

information regarding doses—that the injection is

related problem, a cyst in the ovaries, a problem

given after every three months, and by doing so,
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a child is not conceived, and that mostly, there is

the husbands of clients who come from villages,

no problem (with its use). But it is important to

don’t get involved. (Dr. M, age group 40–49)

also tell them about one side effect of injectable

It is important to involve the husband because it

contraceptives and that is, secondary amenorrhoea.

is the decision of both the husband and the wife.

If we don’t provide information about this side

If a woman accepts a method on her own, and

effect to the client, she will blame us if she

if her husband or other family members, like her

happens to suffer from it later. (Dr. H, age

mother-in-law or sister-in–law, tell her that she

group 30–39)

will have to face many problems by using the

We have to assess her family background,

method, she will not be able to continue its use

her history, and do her physical screening. A

and will drop the method. Subsequently, even if

particular method may not be suitable for

she doesn’t wish to, she may become pregnant. So,

certain clients, and even so, not for her entire

by involving the husband, the use (continuation)

reproductive life. If a woman comes after delivery,

of the method will improve. (Dr. N, age

we prescribe the oral pill. We also need to see the

group 40–49)

age of her last child and which method she wishes

Some health care providers indicated that they

to adopt. (Dr. L, age group 50+)

specifically requested the husband to attend the

Several health care providers discussed the

counselling session if the woman permitted. For

importance of including the husband in the

example:

counselling session, although at least in one case,

Yes. I call both; I call the husband specially.

the health care provider maintained that even when

(Dr. I, age group 30–39)

husbands attended the counselling session, they rarely
participated or asked questions during the discussion.

During counselling, we also involve the husband

Other health care providers highlighted the link

because both should know what is happening.

between the husband’s involvement and the quality

(Dr. G, age group 50+)

of subsequent method use, and the perception that

A few health care providers remarked that

many women would not adopt a method without

husbands were more likely to comprehend

having discussed it with their husband. For example:

instructions than were women or that the husband’s

If both husband and wife are involved then

consent was required, and hence it was important

acceptance is good; especially women who are

that the husband also attended the counselling

educated want to take a decision after discussing

session. For example:

with their husband. (Dr. K, age group 40–49)

If the woman does not understand (the

Clients who belong to urban areas, generally come

instructions), we tell her to call her husband and

with their husband and he wishes to know which

explain them to him; later, we do whatever they

method is good for them, what are the advantages

desire. (Dr. A, age group 50+)

and disadvantages of the method, when to return

The husband should be involved because the

and what they can do or not do. In particular,

consent of both is required. (Dr. H, age

clients who are educated and whose husband is

group 30–39)

also educated, wish to have full information, but
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Mostly, women take one or two doses, then

Health care providers were fairly unanimous in
their perception that the final decision on which

discontinue. They think that irregular menses will

method to adopt was taken by the client, either on

affect their health and so they discontinue the

her own, or together with her husband.

injection. (Dr. C, age group 50+)

Health care provider perceptions
about follow-up, discontinuation and
switching

Because people have this thing in their mind that

Health care providers were mixed in their

contraceptives. (Dr. G, age group 50+)

menstrual blood is dirty blood and if it stays
inside the body, it will harm the body. This is
why most women discontinue using injectable

perceptions about the duration of use of injectable

They take around seven to eight doses, then they

contraceptives, with a few noting that their clients

don’t come; they drop the method because of side

tended to use the method for over a year and others

effects. (Dr. D, age group 30–39)

noting that women rarely continued beyond two
doses. There was more consistency across health

Half of all women discontinue it (injectable

care providers in terms of the factors underlying

contraceptives) because of the problem of

discontinuation, with almost all health care providers

amenorrhoea. (Dr. G, age group 50+)

noting that the experience of side effects, specifically

Women stop taking injectables because of the fear

menstrual disturbances, was a leading reason for

that if they don’t get their periods, other problems

method discontinuation. For example:

will occur. They tell me that their family

Ninety percent of clients come on time and, on

members say that it is necessary that menses

average, take four to five doses. (Dr. J, age

should happen and bleeding should occur.

group 50+)

(Dr. O, age group 40–49)

Women are happy with this method and they

In a few cases, weight gain was also mentioned

come regularly for the next dose. (Dr. P, age

as a reason for discontinuation. Some health

group 50+)

care providers said that women discontinued the

Most clients take seven to eight doses and then

method prematurely because they wished to become
pregnant, associating the method with delayed return

discontinue. (Dr. K, age group 40–49)

to fertility. For example:

In some exceptional cases, women may take
injectables for four to five years, but mostly,

After three to four doses, they stop coming because

women take four to eight doses only. (Dr. N, age

of the side effect of weight gain. (Dr. E, age

group 40–49)

group 30–39)

Mostly, women are irregular. After taking the

Women know that after stopping injectables, it

first, second or third dose, they won’t come back

will take one year to conceive. So, they stop after

for additional doses. (Dr. C, age group 50+)

four to five doses. (Dr. H, age group 30–39)

If menses stops, they think they have conceived

Finally, some health care providers stated that the

and discontinue the method (Dr. A, age

inconvenience of having to visit the facility every

group 50+)

three months dissuaded women from continuing
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Health care provider perceptions
about the inclusion of injectable
contraceptives in the national
programme

injectable contraceptive use. In contrast, the Cu-T
was seen as a more convenient one-time solution,
and oral contraceptives were more easily accessible.
For example:
One problem is coming every three months

Almost all health care providers who discussed their

(for the injection). In some homes, there is not

views about the inclusion of injectable contraceptives

much care for women and there is no one to

in the national programme were positive about

accompany them; so, they discontinue. (Dr. B,

the inclusion of the method. Several health care

age group 40–49)

providers perceived that the inclusion of injectable
contraceptives in the programme would enhance the

Health care providers were also asked about

basket of methods available to women and thereby

whether women who discontinued injectable

offer them greater choice:

contraceptive use adopted other methods, and the
preferred method to which they advised women to

(Injectable contraceptives) should be included in

switch. Three methods were typically suggested—

the government sector programme, as one more

tubal ligation, the IUCD and, to a lesser extent, oral

method will be added for women. (Dr. B, age

contraceptives. Each method was perceived to have

group 40–49)

particular advantages: tubal ligation for those who

Yes. It is a good method and should be included.

had attained their family size, the IUCD for those

By doing so, one more methods will be available

who preferred a one-time method with no need

for women; it will be easily available to them.

for follow up, and oral contraceptives for women

(Dr. H, age group 30–39)

for whom regular menstruation was important. For
example:

Yes. It is a very good method. According to me,
it should also be included in the government

Women with two to three children get their

programme. If it is introduced in the government

sterilisation done. (Dr. K, age group 40–49)

programme, it will be a fortunate thing for

After discontinuing injections, they prefer the

women because at this centre, I have seen that

IUCD and not (oral contraceptive) pills as

within two months of delivery, the woman

they are afraid they will forget to take the pill

conceives again. Even after delivering in a

regularly. (Dr. C, age group 50+)

hospital, she doesn’t use any contraceptive
because no one informs her about anything

Pills, so that menses is regular. (Dr. F, age

(contraception). (Dr. J, age group 50+)

group 40–49)

This method should be available in villages the

After (discontinuing) injectables, they prefer

way it is available in cities...there is a shortage of

multiload (Cu-T). Women prefer the Cu-T

this method in rural areas; it should be available to

because it can be removed at any time in case of

women at their doorstep. (Dr. L, age group 50+)

any problem. (Dr. G, age group 50+)

Yes. It is a good method...if it becomes available,

Women who discontinue using injectables, get

women will get one more choice, and a method

their tubectomy done if they don’t want more

with few side effects. (Dr. N, age group 40–49)

children, (Dr. L, age group 50+)
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Yes. It is a very good method. The failure rate

The side effects of injectables remain for such

is very low and there is no need for surgery.

a long time that we are not sure about the

Therefore, it is a better method than sterilisation.

method... a lot of research is needed before

(Dr. P, age group 50+)

including it in the government programme.
(Dr. O, age group 40–49)

Others argued that its inclusion in the programme
would be advantageous, but must be accompanied

Several health care providers agreed that injectable

by good counselling and follow-up. For example:

contraceptives were an effective and safe method, but
believed that their side effects deterred women from

It is a good contraceptive method and should be

adopting the method. For example:

included (in the government programme), but
counselling and awareness about the method is

Injectables are a good method but they can

required. (Dr. B, age group 40–49)

be used only for a short period, for keeping
a gap of a maximum of three years. But for

Yes. It is a good method and should be included

longer durations, it is not so—for example, if a

(in the government programme), provided there

woman is 30 years old and she wants lifetime

is proper follow up, because there is no use in

service, (contraceptive protection throughout her

taking just one dose for three months.

reproductive years), it will not be appropriate

(Dr. C, age group 50+)

to give her injectable contraceptives for 15 years

Wherever these (contraception) facilities are

because other problems could arise. (Dr. K, age

provided, injectable contraceptives should be

group 40–49)

included. However, service providers should be

Regarding injectable contraceptives, I would just

fully trained and the other staff should also have

like to say that it is a very good method but

information regarding injectables, how they act

it is accompanied by the problem of secondary

in the body and so on, because if counselling

amenorrhoea. (Dr. J, age group 50+)

is good, the method will be accepted effectively.
At many private places, clients are just given

Summary

injectable contraceptives and don’t receive full
information regarding the method. Therefore,

In-depth interviews with health care providers

they come to us later with complaints—because

corroborated many of the issues raised by women

they have half (inadequate) information and lack

who had used injectable contraceptives and those

of awareness about the method, no knowledge

seeking to adopt a contraceptive method. Most

of contraception.... If we provide correct and

health care providers noted that a number of their

complete information to women who are less

clients had adopted injectable contraceptives and

educated, its acceptance will increase. (Dr. K, age

that interest in the method was frequently expressed.

group 40–49)

However, they were mixed about their views on
the appropriateness of injectable contraceptives

Yes, provided that (it is introduced) after doing

as a viable method for their clientele. Almost all

a complete study of the side effects of injectable

agreed that it is a safe and effective method, but

contraceptives. It will be good if it is subsequently

expressed concerns about the side effects of the

brought into the government programme. (Dr. I,

method. Several health care providers indicated

age group 30–39)
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that they would recommend the method to only

that may occur. All health care providers indicated

certain categories of women, for example, those

that they informed women about such side effects

who do not want another child, or are older. Many

as amenorrhoea and heavy bleeding, and that they

noted that menstrual disturbances made injectable

should return to the clinic if they experienced these.

contraceptives an unattractive option for women,

Other side effects were mentioned less frequently

arguing that neither heavy bleeding nor amenorrhoea

(weight gain, for example). Several health care

were acceptable side effects for women. A number of

providers discussed the importance of including the

health care providers also mentioned that injectable

husband in the counselling session, highlighting

contraceptives were not an appropriate non-terminal

the link between the husband’s involvement and

method for women intending to have another

the quality of subsequent method use, and the

pregnancy on discontinuation of the method,

perception that many women would not adopt

that time to conception was far longer than that

a method without having discussed it with their

associated with the Cu-T or oral contraceptives.

husband. All health care providers emphasised that

It is notable that not a single health care provider

the final decision on method use was made by the

specifically reported recommending injectable

woman herself, alone or together with her husband.

contraceptives to recently delivered or lactating

Health care providers held different views about

women, although the method is recommended for

the average duration of injectable contraceptive

such women.

use among their clients, some suggesting that

Health care providers expressed different views

women discontinued after the first or second

about offering injectable contraceptives to poor or

injection and others suggesting that women used

poorly educated women. Most health care providers

the method for considerably longer periods. In

maintained that the educational attainment status

contrast, they were fairly unanimous about the

of their clients did not affect their decision to offer

key reasons for discontinuation. Leading reasons

injectable contraceptives to them. Some, however,

were the inconvenience of returning to the facility

perceived that the poor and the poorly educated

every three months for re-injections, cost, and side

found it more difficult than others to comprehend

effects, notably menstrual disturbances. Health care

how the method works, and still others feared that

providers noted, for example, that many women

the poor would not be able to bear the cost of re-

who experienced heavy bleeding or irregular

injections. This perception did not, however, deter

periods discontinued using injectable contraceptives,

most of these health care providers from offering

fearing that they had a serious disease. Those who

the method to poorly educated and poor women;

experienced amenorrhoea were reported to fear that

indeed, they reported that they spent more time

they were pregnant, and discontinued the method

explaining it to them than to others, and even

as a result. Additionally, because of cultural practices

recommended that the method be made more widely

that forbid menstruating women from entering the

available to rural women through the programme.

kitchen or praying, women who experienced heavy
bleeding or irregular menstruation discontinued using

For the most part, health care providers indicated
that counselling entailed the provision of such

injectable contraceptives because it affected their

information as the mechanics of the method (how

ability to perform these regular tasks. Several also

often it must be taken) and the kind of side effects

noted that weight gain and the long waiting time to
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conception following discontinuation were additional

of methods available to women would increase and

reasons for discontinuing the method. Health care

provide women with greater choice. However, they

providers reported that method switching was

argued strongly for certain prerequisites, such as

evident among women who discontinued using

comprehensive and sensitive counselling and effective

injectable contraceptives for method-related reasons,

follow up, for example. A few were sceptical; they

and that the two methods to which women most

believed that even with such improvements in the

commonly switched were tubal ligation and the

quality of services, few women in India would adopt

IUCD.

or continue using injectable contraceptives because
their side effects, notably menstrual disturbances,

Finally, health care providers were, for the most

would discourage its use for both health and socio-

part, in favour of including injectable contraceptives

cultural reasons.

in the national programme, in order that the basket
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The way forward
This chapter highlights the lessons learned for

enhance women’s options and enable them to select

programming from the findings of our study, drawn

the one whose features most suit their needs.

from the experiences and perspectives of women who

Include a component of injectable
contraceptives in the training offered to a
range of health care providers

had used injectable contraceptives, women seeking
contraception, and health care providers who offer
injectable contraceptives to women. The findings
of the study suggest a number of priority areas for

Findings have suggested that health care providers

action.

who serve injectable contraceptive users may not be
fully aware of the advantages and disadvantages of

Meet the demand for injectable
contraceptives by including the method in
the basket of contraceptives provided in
public sector facilities

injectable contraceptives, the full range of side effects
that are and are not associated with
injectable contraceptives, and the counselling needs
of potential users. It is important, therefore, to

Findings highlight that there is considerable interest

include a module on injectable contraceptives in

in adopting injectable contraceptives and clearly

the contraception-related training offered to a range

a demand for a safe and effective non-terminal

of health care providers. For example, health care

method that allows women to control their fertility

providers must be made aware of the appropriateness

confidentially, that does not require daily attention

of injectable contraceptives for women who are

and that does not require to be inserted. Relatively

recently delivered and lactating. Similarly, they

low continuation rates are associated with injectable

should be trained to recognise that injectable

contraceptives globally and the finding should not

contraceptives may satisfy the needs of women at

be interpreted as a lack of demand. Indeed, the

different stages of the life cycle, for example, a newly

finding that more than one-fifth of all injectable

delivered woman who wishes to space her next

contraceptive users continued the method for 12

pregnancy, or a woman who is not medically eligible

months reiterates that there exists a demand for the

for an IUCD or does not want to have an IUCD

method among certain groups of women. At the

inserted but is looking for a long-acting method. At

same time, evidence that many more discontinue

the same time, they should be trained to appreciate

injectable contraceptive use and immediately switch

that for some women, common side effects would

to a different method, thereby remaining protected

likely be an intolerable disturbance in everyday life,

against unintended pregnancy, suggests that injectable

and hence, should be equipped to counsel women

contraceptives play an important role in women’s

so as to enable the woman to arrive at an informed

overall contraceptive strategies. Expanding the basket

decision about whether or not to adopt injectable

of contraceptives available to women will, therefore,

contraceptives.
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Given that a number of women from our study

making. Provided that the woman agrees, it is

were drawn from rural areas, it is important that

important that counselling includes both the woman

training for frontline health workers, such as ANMs,

and her husband and that both are made fully

ASHAs and AWWs, should also include information

cognisant of possible side effects.

about injectable contraceptives, how they function

As far as counselling is concerned, health care

and where they can be obtained, as well as basic

providers must be trained to ensure that counselling

information about potential side effects and how

encompasses the full range of side effects associated

these should be managed.

with injectable contraceptives, as well as the action
that the woman should take in case these side

Expand awareness of injectable
contraceptives at the community level

effects are experienced; the need to ensure that
the woman has understood the implications of the

Findings have confirmed that many women seeking

method proposed, including injectable contraceptives,

to adopt contraceptives were unaware of injectable

must be emphasised. For example, women, and

contraceptives, and at the same time, although the

their husbands if present, must be informed that

method is not available through the programme,

amenorrhoea, irregular menstrual cycles and heavy

a sizeable number of women do indeed opt for it.

bleeding occur to large numbers of injectable

It is important, therefore, that efforts are made to

contraceptive users, that some women may gain

inform communities, and women in particular, about

weight, and that return to fertility may be slower

injectable contraceptives, how they function, their

than in the case of other contraceptives. Counselling

cost, and where they can be obtained, as well as

sessions must also make women feel supported in

basic information about potential side effects.

case side effects are experienced, and emphasise
the appropriateness of follow-up visits and phone

Improve the quality of care and
counselling provided to injectable
contraceptive users

calls in case the woman has concerns. Our finding
that continuation rates were significantly higher
among women who were provided comprehensive
counselling underscores the critical role that health

Findings suggest a disconnect between the views

care providers play in ensuring method satisfaction.

of health care providers on the comprehensiveness
of counselling provided and women’s views about

Make special efforts to inform injectable
contraceptive users and potential users
about health-related side effects

the comprehensiveness of counselling received from
health care providers with regard to injectable
contraceptives. This disconnect highlights the need
for health care providers to ensure that women are

Menstrual disturbances and weight gain are

indeed making an informed choice, that they fully

common and well-known side effects of injectable

understand the implications of likely side effects for

contraceptives, and return to fertility is typically

their life. Health care providers have acknowledged

longer among women who discontinue using

the importance of including husbands in the

injectable contraceptives than other methods. Women

counselling session, and findings have confirmed

considering use of the method must be supported

that continuation beyond the first dose is indeed

in making an informed decision, given these

influenced by the role of the husband in decision-

three key concerns. Irregular prolonged bleeding,
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amenorrhoea and/or heavy bleeding occur among

Efforts are needed that enable women to obtain re-

most users of injectable contraceptives at some

injections closer to their homes and at reduced cost;

point while using the method, and women should

the introduction of the method into the programme

be informed about this likelihood and the fact that

would go a long way in doing so.

side effects are typically not harmful. Although

Conclusion

injectable contraceptives are a reversible method of
fertility regulation, women also need to be informed

In short, findings suggest that there is a demand for

that since the method is long-acting, it cannot

injectable contraceptives among women, and that

easily be discontinued or removed from the body

both women and health care providers perceive a

if a complication occurs or if pregnancy is desired.

number of advantages associated with the method. As

Counselling sessions should be supplemented by

is well known, injectable contraceptives may not suit

pamphlets and easy-to-read materials that highlight

the lifestyle of many Indian women and our findings

these side effects, emphasise that they are not

have confirmed that the method was adopted and

harmful, and advise users about the action to take in

was continued for one year or more, by relatively few

case they are experienced.

women. Nevertheless, the fact that it was adopted
by one in ten women seeking contraception, and

Reduce barriers to accessing supplies

was continued for one year or more by one in five

Findings have shown that 16 percent of all women

women who adopted the method, reiterates that

who had discontinued using injectable contraceptives

for a significant minority of women, its advantages

and between 12 percent and 28 percent of women

exceed its disadvantages on balance. We conclude

who had discontinued using the method after various

that there is indeed a demand for the method among

doses reported difficulty in accessing re-supplies. The

this minority of women, and that the inclusion of

leading access-related barrier was the inconvenience

injectable contraceptives in the basket of methods

of accessing the facility every three months for

offered under the national programme, along with

re-injections. Long distances, limited freedom of

appropriate emphasis on health care provider training

movement and unavailability of an escort, and time

and on ensuring informed choice, will expand

spent in travelling to the facility for re-injections

women’s contraceptive choices and help in ensuring

were significant deterrent to method continuation.

their reproductive rights.
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